1
|
Dormegny-Jeanjean LC, Mainberger OAE, de Crespin de Billy C, Obrecht A, Danila V, Erb A, Arcay HM, Weibel S, Blanc F, Meyer G, Tomsa M, Bertschy G, Duval F, Foucher JR. Safety and tolerance of combination of monoamine oxidase inhibitors and direct dopamine agonists in adults and older adults with highly resistant depression. Encephale 2024; 50:137-142. [PMID: 37005193 DOI: 10.1016/j.encep.2023.01.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Revised: 01/09/2023] [Accepted: 01/27/2023] [Indexed: 04/03/2023]
Abstract
INTRODUCTION Dopamine (DA) is likely to be involved in some depressive dimensions, such as anhedonia and amotivation, which account for a part of treatment-resistant forms. Monoamine oxidase inhibitors (MAOI) and direct D2 and D3 receptors agonists (D2/3r-dAG) are known to help, but we lack safety data about their combined usage. We report on safety and tolerance of the MAOI+D2r-dAG combination in a clinical series. METHOD All patients referred to our recourse center for depression between 2013 and 2021 were screened to select those who did receive the combo. Data were extracted from clinical files. RESULTS Sixteen patients of 60±17 years of age (8 women, 7 with age>65years, all suffered from treatment resistant depression, 7 with bipolar disorder) received the combo. There were no life-threatening adverse effects (AE). However, AE were reported by 14 patients (88%) most of which were mild and consisted of insomnia, nausea, nervousness, confusion, impulse control disorder and/or "sleep attacks". One patient presented a serious AE requiring a short hospitalization for confusion. Intolerance led to failure to introduce treatment in two patients (13%). The retrospective non-interventional design, the variety of molecules, and the modest sample size limited the scope of these results. CONCLUSION There was no life-threatening safety issue in combining MAOI and D2/3r-dAG, especially regarding cardiovascular side effects. The systematic screening of AE might account for their frequency, but these precluded the treatment in only two patients. Comparative studies are needed to assess the efficacy of this new combination.
Collapse
Affiliation(s)
- L C Dormegny-Jeanjean
- Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), University Hospital of Strasbourg, 67000 Strasbourg, France; CNRS UMR 7357 iCube, neurophysiology, FMTS, University of Strasbourg, 67000 Strasbourg, France.
| | - O A E Mainberger
- Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), University Hospital of Strasbourg, 67000 Strasbourg, France; CNRS UMR 7357 iCube, neurophysiology, FMTS, University of Strasbourg, 67000 Strasbourg, France
| | - C de Crespin de Billy
- Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), University Hospital of Strasbourg, 67000 Strasbourg, France; CNRS UMR 7357 iCube, neurophysiology, FMTS, University of Strasbourg, 67000 Strasbourg, France
| | - A Obrecht
- Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), University Hospital of Strasbourg, 67000 Strasbourg, France; CNRS UMR 7357 iCube, neurophysiology, FMTS, University of Strasbourg, 67000 Strasbourg, France
| | - V Danila
- Department of Psychiatry "pole 8/9", Rouffach Psychiatric Hospital, 68250 Rouffach, France
| | - A Erb
- Department of Psychiatry "pole 8/9", Rouffach Psychiatric Hospital, 68250 Rouffach, France
| | - H M Arcay
- CNRS UMR 7357 iCube, neurophysiology, FMTS, University of Strasbourg, 67000 Strasbourg, France
| | - S Weibel
- Department of Psychiatry and Mental Health-University Hospital of Strasbourg, University of Strasbourg, 67000 Strasbourg, France; Inserm UMR 1114, Physiopathology and Cognitive Psychopathology of Schizophrenia, University of Strasbourg, 67000 Strasbourg, France
| | - F Blanc
- CNRS UMR 7357 iCube, neurophysiology, FMTS, University of Strasbourg, 67000 Strasbourg, France; Geriatrics Department and Expert Center for Neurocognitive Disorders, University Hospital of Strasbourg, University of Strasbourg, 67000 Strasbourg, France
| | - G Meyer
- Pharmacopsy Alsace, Clinical Pharmacy Department, Établissement Public de Santé Alsace Nord, Brumath, France; Pharmacy Department, University Hospital of Strasbourg, 67000 Strasbourg, France
| | - M Tomsa
- Department of Psychiatry "pole 8/9", Rouffach Psychiatric Hospital, 68250 Rouffach, France
| | - G Bertschy
- Department of Psychiatry and Mental Health-University Hospital of Strasbourg, University of Strasbourg, 67000 Strasbourg, France; Inserm UMR 1114, Physiopathology and Cognitive Psychopathology of Schizophrenia, University of Strasbourg, 67000 Strasbourg, France
| | - F Duval
- Department of Psychiatry "pole 8/9", Rouffach Psychiatric Hospital, 68250 Rouffach, France
| | - J R Foucher
- Non-Invasive neuroModulation Center of Strasbourg (CEMNIS), University Hospital of Strasbourg, 67000 Strasbourg, France; CNRS UMR 7357 iCube, neurophysiology, FMTS, University of Strasbourg, 67000 Strasbourg, France
| |
Collapse
|
2
|
Fernández-Eulate G, Alfieri G, Spinazzi M, Ackermann-Bonan I, Duval F, Solé G, Caillon F, Mercier S, Pereon Y, Magot A, Pegat A, Salort-Campana E, Chabrol B, Gorokhova S, Krahn M, Biancalana V, Evangelista T, Behin A, Metay C, Stojkovic T. Phenotype variability and natural history of X-linked myopathy with excessive autophagy. J Neurol 2024:10.1007/s00415-024-12298-0. [PMID: 38517523 DOI: 10.1007/s00415-024-12298-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 02/26/2024] [Accepted: 03/01/2024] [Indexed: 03/24/2024]
Abstract
OBJECTIVE X-linked myopathy with excessive autophagy (XMEA) linked to the VMA21 gene leads to autophagy failure with progressive vacuolation and atrophy of skeletal muscles. Current knowledge of this rare disease is limited. Our objective was to define the clinical, radiological, and natural history of XMEA. METHODS We conducted a retrospective study collecting clinical, genetic, muscle imaging, and biopsy data of XMEA patients followed in France and reviewed the literature for additional cases. RESULTS Eighteen males had genetically confirmed XMEA in France, carrying four different VMA21 variants. Mean age at disease onset was 9.4 ± 9.9 (range 1-40) years. In 14/18 patients (77.8%), onset occurred during childhood (< 15 years); however in four patients, the disease started in adulthood. Patients had anterior and medial compartment thigh muscle weakness, distal contractures (56.3%), elevated CK levels (1287.9 ± 757.8 U/l) and autophagic vacuoles with sarcolemmal features on muscle histopathology. Muscle MRI (n = 10) showed a characteristic pattern of lower limb muscle involvement. In 11 patients, outcome measures were available for an average follow-up period of 10.6 ± 9.8 years and six of them show disease progression. Mean change of functional outcomes was 0.5 ± 1.2 points for Brooke and 2.2 ± 2.5 points for Vignos score, 7/16 patients (43.8%) needed a walking aid and 3/16 (18.8%) were wheelchair-bound (median age of 40 years old, range 39-48). The variant c.164-7 T > G was associated with a later onset of symptoms. Respiratory insufficiency was common (57.1%) but cardiac involvement rare (12.5%). INTERPRETATION XMEA has variable age of onset, but a characteristic clinical, histopathological, and muscle imaging presentation, guiding the diagnosis. Although slowly, motor disability progresses with time, and relevant genotype-phenotype correlations will help design future clinical trials.
Collapse
Affiliation(s)
- Gorka Fernández-Eulate
- Nord/Est/Ile-de-France Neuromuscular Diseases Reference Center, Institut de Myologie, Pitié-Salpêtrière Hospital, APHP, 47-83 Bd de L'Hôpital, 75013, Paris, France.
| | - Girolamo Alfieri
- Nord/Est/Ile-de-France Neuromuscular Diseases Reference Center, Institut de Myologie, Pitié-Salpêtrière Hospital, APHP, 47-83 Bd de L'Hôpital, 75013, Paris, France
- Azienda Ospedaliera Universitaria Sant'Andrea, Rome, Italy
| | - Marco Spinazzi
- Neuromuscular Diseases Reference Center, Neurology Department, CHU Angers, Angers, France
| | | | - Fanny Duval
- Neuromuscular Diseases Reference Center "AOC", Nerve-Muscle Unit, Pellegrin Hospital, CHU Bordeaux, Bordeaux, France
| | - Guilhem Solé
- Neuromuscular Diseases Reference Center "AOC", Nerve-Muscle Unit, Pellegrin Hospital, CHU Bordeaux, Bordeaux, France
| | | | - Sandra Mercier
- Medical Genetics Department, Neuromuscular Diseases Reference Center "AOC", CHU Nantes, Nantes, France
| | - Yann Pereon
- Neuromuscular Diseases Reference Center "AOC", Laboratoire d'Explorations Fonctionnelles, CHU de Nantes, FILNEMUS, Euro-NMD, Nantes, France
| | - Armelle Magot
- Neuromuscular Diseases Reference Center "AOC", Laboratoire d'Explorations Fonctionnelles, CHU de Nantes, FILNEMUS, Euro-NMD, Nantes, France
| | - Antoine Pegat
- Electroneuromyography and Neuromuscular Diseases Unit, PACA-Réunion-Rhône Alpes Neuromuscular Diseases Reference Center, Pierre Wertheimer Hospital, Hospices Civils de Lyon, Lyon, France
| | | | - Brigitte Chabrol
- Neuromuscular Diseases and ALS Reference Center, FILNEMUS, CHU La Timone, APHM, Marseille, France
| | - Svetlana Gorokhova
- Medical Genetics Department, CHU La Timone Enfants, APHM, Aix-Marseille University, Inserm, U1251-MMG, Marseille, France
| | - Martin Krahn
- Medical Genetics Department, CHU La Timone Enfants, APHM, Aix-Marseille University, Inserm, U1251-MMG, Marseille, France
| | - Valerie Biancalana
- Diagnostic Genetics Laboratory, CRU Strasbourg, Strasbourg University, Strasbourg, France
| | - Teresinha Evangelista
- Muscle Pathology Unit, Institut de Myologie, Nord/Est/Ile-de-France Neuromuscular Diseases Reference Center, Pitié-Salpêtrière Hospital, APHP, Paris, France
| | - Anthony Behin
- Nord/Est/Ile-de-France Neuromuscular Diseases Reference Center, Institut de Myologie, Pitié-Salpêtrière Hospital, APHP, 47-83 Bd de L'Hôpital, 75013, Paris, France
| | - Corinne Metay
- Cardiomyogenetics and Molecular and Cellular Myogenetics Unit, Institut de Myologie, Pitié-Salpêtrière Hospital, APHP, Paris, France
| | - Tanya Stojkovic
- Nord/Est/Ile-de-France Neuromuscular Diseases Reference Center, Institut de Myologie, Pitié-Salpêtrière Hospital, APHP, 47-83 Bd de L'Hôpital, 75013, Paris, France
| |
Collapse
|
3
|
Hazard M, Duval F, Dutriaux C, Beylot-Barry M, Pham-Ledard A, Quereux G, Amini-Adle M, Heidelberger V, Aubin F, Saint-Jean M, Nardin C, Abed S, Leccia MT, Mansard S, Prey S, Khammari A, Dréno B, Gérard E. Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC). J Neurol 2024; 271:1473-1482. [PMID: 38052771 DOI: 10.1007/s00415-023-12105-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2023] [Revised: 11/06/2023] [Accepted: 11/08/2023] [Indexed: 12/07/2023]
Affiliation(s)
- Madeleine Hazard
- Department of Dermatology, Hospital Dupuytren 2, UHC of Limoges, Limoges, France
| | - Fanny Duval
- Department of Medical Neurology, Hospital Pellegrin, UHC of Bordeaux, Bordeaux, France
| | - Caroline Dutriaux
- Department of Dermatology, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France
- BRIC (Bordeaux Institute of Oncology), UMR1312, INSERM, Univ. Bordeaux, 33000, Bordeaux, France
| | - Marie Beylot-Barry
- Department of Dermatology, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France
- BRIC (Bordeaux Institute of Oncology), UMR1312, INSERM, Univ. Bordeaux, 33000, Bordeaux, France
| | - Anne Pham-Ledard
- Department of Dermatology, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France
- BRIC (Bordeaux Institute of Oncology), UMR1312, INSERM, Univ. Bordeaux, 33000, Bordeaux, France
| | - Gaelle Quereux
- Department of Dermatology, UHC of Nantes, France, CIC 1413, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, 44000, Nantes, France
| | | | | | - François Aubin
- Department of Dermatology, UHC of Besançon, Besançon, France
| | - Mélanie Saint-Jean
- Department of Oncology, Cancer Comprehensive Center, Saint-Herblain, France
| | - Charlée Nardin
- Department of Dermatology, UHC of Besançon, Besançon, France
| | - Safia Abed
- Department of Dermatology, Military Training Hospital of Sainte Anne, Toulon, France
| | | | - Sandrine Mansard
- Department of Dermatology, Estaing Hospital, Clermont-Ferrand, France
| | - Sorilla Prey
- Department of Dermatology, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France
- BRIC (Bordeaux Institute of Oncology), UMR1312, INSERM, Univ. Bordeaux, 33000, Bordeaux, France
| | - Amir Khammari
- Department of Dermatology, UHC of Nantes, France, CIC 1413, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, 44000, Nantes, France
| | - Brigitte Dréno
- Department of Dermatology, UHC of Nantes, France, CIC 1413, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, 44000, Nantes, France
| | - Emilie Gérard
- Department of Dermatology, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France.
- BRIC (Bordeaux Institute of Oncology), UMR1312, INSERM, Univ. Bordeaux, 33000, Bordeaux, France.
| |
Collapse
|
4
|
Mathis S, Solé G, Damon-Perrière N, Rouanet-Larrivière M, Duval F, Prigent J, Nadal L, Péréon Y, Le Masson G. Clinical Neurology in Practice: The Tongue (part 2). Neurologist 2024; 29:59-69. [PMID: 37639532 DOI: 10.1097/nrl.0000000000000510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/31/2023]
Abstract
BACKGROUND The tongue is an essential organ for the development of certain crucial functions such as swallowing and speech. The examination of the tongue can be very useful in neurology, as the various types of lingual alterations can lead to certain specific diagnoses, the tongue being a kind of 'mirror' of some neurological function. REVIEW SUMMARY To discuss the elements of clinical examination of the tongue in relation to neurological disorders. After reviewing the different superficial lesions of the tongue, we deal with various movement disorders of the tongue (fasciculations/myokimia, orolingual tremor, choreic movements of the tongue, dystonia of the tongue, lingual myoclonus, and psychogenic movements), disorders of taste and lingual sensitivity and lingual pain. CONCLUSIONS Examination of the tongue should not be limited to studying its motility and trophicity. It is equally important to check the sensory function and understand how to interpret abnormal movements involving the tongue. This study also aimed to demonstrate the importance of nonmotor tongue function in neurological practice.
Collapse
Affiliation(s)
- Stéphane Mathis
- Department of Neurology, Muscle-Nerve Unit, University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
- Referral Center for Neuromuscular Diseases 'AOC', University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
- ALS Center, University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
| | - Guilhem Solé
- Department of Neurology, Muscle-Nerve Unit, University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
- Referral Center for Neuromuscular Diseases 'AOC', University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
| | - Nathalie Damon-Perrière
- Department of Clinical Neurophysiology, University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
- Department of Movement disorders, University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
| | - Marie Rouanet-Larrivière
- Department of Clinical Neurophysiology, University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
| | - Fanny Duval
- Department of Neurology, Muscle-Nerve Unit, University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
- Referral Center for Neuromuscular Diseases 'AOC', University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
| | - Julia Prigent
- Department of Neurology, Muscle-Nerve Unit, University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
| | - Louis Nadal
- Department of Neurology, Muscle-Nerve Unit, University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
| | - Yann Péréon
- CHU Nantes, Reference Centre for Neuromuscular Diseases AOC, Filnemus, Nantes, France
| | - Gwendal Le Masson
- Department of Neurology, Muscle-Nerve Unit, University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
- Referral Center for Neuromuscular Diseases 'AOC', University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
- ALS Center, University Hospitals of Bordeaux (CHU Bordeaux - Pellegrin Hospital), University of Bordeaux, Bordeaux, France
| |
Collapse
|
5
|
Bonnefin C, Duval F, Rouanet M, Kostine M, Gerard E. Case report: Parsonage-turner syndrome in a melanoma patient treated by BRAF/MEK inhibitors after immune checkpoint inhibitors. Front Oncol 2023; 13:1268693. [PMID: 38192629 PMCID: PMC10773839 DOI: 10.3389/fonc.2023.1268693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 11/06/2023] [Indexed: 01/10/2024] Open
Abstract
Introduction Combination molecular BRAF/MEK inhibitors targeted therapy has been shown to improve overall survival in patients with BRAF V600 mutated unresectable or metastatic melanoma. Most patients treated with BRAF/MEK inhibitors will experience adverse events but neurological adverse events (nAEs) remain rare. Case report A 42-year-old woman diagnosed with metastatic melanoma presented with an intense pain in the left shoulder 7 days after the beginning of encorafenib/binimetinib after immune checkpoint inhibitors (ICI) combination. No other triggering factors were identified. Electromyogram performed one month after the pain onset revealed a left brachial plexopathy suggestive of a Parsonage-Turner syndrome. The weakness slowly improved with intensive rehabilitation and targeted therapies were continued. Conclusion We report the first case of Parsonage-Turner syndrome in a melanoma patient treated with encorafenib/binimetinib following checkpoint inhibitors combination.We cannot rule out the implication of ICI in the development of this syndrome but the rapid onset of the symptoms after the beginning of targeted therapies makes their involvment more likely.Given the increased use of BRAF/MEK inhibitors in managing of stage III and IV melanoma, as well as the development in stage II, clinicians should be aware of this potential side effect.
Collapse
Affiliation(s)
- Charlotte Bonnefin
- Department of Dermatology, Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France
| | - Fanny Duval
- Atlantique Occitanie Caraïbe (AOC) Referral Center for Neuromuscular Diseases, Neurology and Neuromuscular Diseases Department, Filière Neuromusculaire (FILNEMUS), Bordeaux University Hospital, Bordeaux, France
| | - Marie Rouanet
- Department of Neurology, Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France
| | - Marie Kostine
- ImmunoConcEpT, Université (Univ.) Bordeaux, Bordeaux, France
- Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France
| | - Emilie Gerard
- Department of Dermatology, Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France
| |
Collapse
|
6
|
Pijnenburg L, Giannini M, Bouchard-Marmen M, Arnaud L, Barsotti S, Bellando-Randone S, Bernardi L, Bini P, Blagojevic J, Codullo V, Couderc M, De Moreuil C, Dernis E, Diamanti L, Dubost JJ, Duval F, Emmi G, Galempoix JM, Geny B, Gottenberg JE, Groza M, Guffroy A, Guichard I, Guilpain P, Hervier B, Hudson M, Iaccarino L, Iannone F, Lebrun D, Marchioni E, Mariampillai K, Maurier F, Mosca M, Nadaj-Pakleza A, Nannini C, Piot JM, Prieto-González S, Poursac N, Rouanet E, Sellam J, Selva-O'Callaghan A, Séverac F, Sibilia J, Sole G, Soulages A, Terrier B, Tournadre A, Troyanov Y, Vernier N, Vesperini V, Viallard JF, Ziane R, Cavagna L, Meyer A. In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case-control study. RMD Open 2023; 9:e003081. [PMID: 37666644 PMCID: PMC10481849 DOI: 10.1136/rmdopen-2023-003081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2023] [Accepted: 06/22/2023] [Indexed: 09/06/2023] Open
Abstract
BACKGROUND Some myopathies can lead to dropped head or bent spine syndrome (DH/BS). The significance of this symptom has not been studied in inflammatory myopathies (IM). OBJECTIVES To assess the significance of DH/BS in patients with IM. METHODS Practitioners from five IM networks were invited to report patients with IM suffering from DH/BS (without other known cause than IM). IM patients without DH/BS, randomly selected in each participating centre, were included as controls at a ratio of 2 to 1. RESULTS 49 DH/BS-IM patients (DH: 57.1%, BS: 42.9%) were compared with 98 control-IM patients. DH/BS-IM patients were older (65 years vs 53 years, p<0.0001) and the diagnosis of IM was delayed (6 months vs 3 months, p=0.009). Weakness prevailing in the upper limbs (42.9% vs 15.3%), dysphagia (57.1% vs 25.5%), muscle atrophy (65.3% vs 34.7%), weight loss (61.2% vs 23.5%) and loss of the ability to walk (24.5% vs 5.1%) were hallmarks of DH/BS-IM (p≤0.0005), for which the patients more frequently received intravenous immunoglobulins (65.3% vs 34.7%, p=0.0004). Moreover, DH/BS-IM patients frequently featured signs and/or complications of systemic sclerosis (SSc), fulfilling the American College of Rheumatology/European Alliance of Associations for Rheumatology criteria for this disease in 40.8% of the cases (vs 5.1%, p<0.0001). Distribution of the myopathy, its severity and its association with SSc were independently associated with DH/BS (p<0.05). Mortality was higher in the DH/BS-IM patients and loss of walking ability was independently associated with survival (p<0.05). CONCLUSION In IM patients, DH/BS is a marker of severity and is associated with SSc (scleromyositis).
Collapse
Affiliation(s)
- Luc Pijnenburg
- Service de rhumatologie, Centre de Référence des Maladies Auto-immunes Systémiques Rares Est Sud-Ouest Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
| | - Margherita Giannini
- Service de rhumatologie, Centre de Référence des Maladies Auto-immunes Systémiques Rares Est Sud-Ouest Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
- Exploration fonctionnelle musculaire, Service de Physiologie Explorations Fonctionnelles Musculaires, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
| | | | - Laurent Arnaud
- Service de rhumatologie, Centre de Référence des Maladies Auto-immunes Systémiques Rares Est Sud-Ouest Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
| | - Simone Barsotti
- Department of Rheumatology and Clinical Immunology Unit, University of Pisa, Pisa, Italy
| | - Silvia Bellando-Randone
- Department of Experimental and Clinical Medicine, Universitaria Careggi, Azienda Ospedaliera, Florence, Italy
| | - Livio Bernardi
- Departement of rheumatology, University of Padova, Padova, Italy
| | - Paola Bini
- Department of neurology, Neurological Institute Mondino, University of Pavia, Pavia, Italy
| | - Jelena Blagojevic
- Department of Experimental and Clinical Medicine, Universitaria Careggi, Azienda Ospedaliera, Florence, Italy
| | - Veronica Codullo
- Rheumatology Division, University and IRCCS Policlinico S. Matteo Foundation Pavia, Pavia, Italy
| | - Marion Couderc
- Service de rhumatologie, Hôpitaux Universitaires de Clermont-Ferrand, Clermont-Ferrand, France
| | - Claire De Moreuil
- Service de médecine interne, Hôpitaux Universitaires de Brest, Brest, France
| | - Emanuelle Dernis
- Service de rhumatologie, Centre hospitalier Le Mans, Le Mans, France
| | - Luca Diamanti
- Department of neurology, Neurological Institute Mondino, University of Pavia, Pavia, Italy
| | - Jean Jacques Dubost
- Service de médecine interne, Hôpitaux Universitaires de Clermont-Ferrand, Clermont-Ferrand, France
| | - Fanny Duval
- Service de neurologie, Hôpitaux Universitaires de Bordeaux, Bordeaux, France
| | - Giacomo Emmi
- Department of Experimental and Clinical Medicine, Universitaria Careggi, Azienda Ospedaliera, Florence, Italy
| | - Jean-Marc Galempoix
- Service de Médecine Interne, Centre Hospitalier de Charleville-Mézières, Charleville-Mézières, France
| | - Bernard Geny
- Exploration fonctionnelle musculaire, Service de Physiologie Explorations Fonctionnelles Musculaires, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
| | - Jacques-Eric Gottenberg
- Service de rhumatologie, Centre de Référence des Maladies Auto-immunes Systémiques Rares Est Sud-Ouest Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
| | - Monica Groza
- Service de médecine interne, Centre hospitalier Colmar, Colmar, France
| | - Aurelien Guffroy
- Service d'immunologie clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares Est Sud-Ouest Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
| | - Isabelle Guichard
- Service de médecine interne, Hôpitaux Universitaires de Saint Etienne, Saint Etienne, France
| | - Philippe Guilpain
- Service de médecine interne, Hôpitaux Universitaires de Montpellierr, Montpellier, France
| | - Baptiste Hervier
- Service de médecine interne, Assistance publique - Hôpitaux de Paris, Saint Louis, Paris, France
| | - Marie Hudson
- Department of medicine, Division of Rheumatology, Jewish General Hospital, McGill University, Montreal, Québec, Canada
| | - Luca Iaccarino
- Departement of rheumatology, University of Padova, Padova, Italy
| | | | - Delphine Lebrun
- Service de Médecine Interne, Centre Hospitalier de Charleville-Mézières, Charleville-Mézières, France
| | - Enrico Marchioni
- Department of neurology, Neurological Institute Mondino, University of Pavia, Pavia, Italy
| | - Kuberaka Mariampillai
- Service de médecine interne, Assistance publique - Hôpitaux de Paris, Saint Louis, Paris, France
| | - Francois Maurier
- Service de médecine interne, Hôpitaux privés de Metz, Metz, France
| | - Marta Mosca
- Department of Rheumatology and Clinical Immunology Unit, University of Pisa, Pisa, Italy
| | - Aleksandra Nadaj-Pakleza
- Service de neurologie, Centre de référence des maladies neuromusculaires, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | | | - Jean-Maxime Piot
- Service de rhumatologie, Centre hospitalier Le Mans, Le Mans, France
| | | | - Nicolas Poursac
- Service de rhumatologie, Centre de Référence des Maladies Auto-immunes Systémiques Rares Est Sud-Ouest, Hôpitaux Universitaires de Bordeaux, Bordeaux, France
| | - Eglantine Rouanet
- Service de rhumatologie, Centre hospitalier Le Mans, Le Mans, France
| | - Jérémie Sellam
- Service de rhumatologie, Hôpital Saint Antoine, Assistance publique - Hôpitaux de Paris, Paris, France
| | | | - François Séverac
- Service de Santé Publique, GMRC; ICube, UMR 7357, Hôpitaux universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
| | - Jean Sibilia
- Service de rhumatologie, Centre de Référence des Maladies Auto-immunes Systémiques Rares Est Sud-Ouest Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
| | - Guilhem Sole
- Service de neurologie, Hôpitaux Universitaires de Bordeaux, Bordeaux, France
| | - Antoine Soulages
- Service de neurologie, Hôpitaux Universitaires de Bordeaux, Bordeaux, France
| | - Benjamin Terrier
- Service de médecine interne, Hôpital Cochin Assistance publique - Hôpitaux de Paris Cochin, Paris, France
| | - Anne Tournadre
- Service de rhumatologie, Hôpitaux Universitaires de Clermont-Ferrand, Clermont-Ferrand, France
| | - Yves Troyanov
- Department of rheumatology, Hôpital Sacre Cœur Montréal, Université de Montréal, Montreal, Québec, Canada
| | - Nathalie Vernier
- Service de médecine interne, Hôpitaux Universitaires de Dijon, Dijon, France
| | | | | | - Rahima Ziane
- Service de médecine interne, Hôpitaux Universitaires de Montpellierr, Montpellier, France
| | - Lorenzo Cavagna
- Rheumatology Division, University and IRCCS Policlinico S. Matteo Foundation Pavia, Pavia, Italy
| | - Alain Meyer
- Exploration fonctionnelle musculaire, Service de Physiologie Explorations Fonctionnelles Musculaires, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
| |
Collapse
|
7
|
Gra M, Pham-Ledard A, Gerard E, Dutriaux C, Beylot-Barry M, Duval F, Carla L, Soulages A, Prey S. Brief Communication: Lambert-Eaton Myasthenic Paraneoplastic Syndrome Associated With Merkel Cell Carcinoma Successfully Treated by Immune Checkpoint Inhibitors: 2 Cases. J Immunother 2023; 46:276-278. [PMID: 37326491 DOI: 10.1097/cji.0000000000000480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Accepted: 05/19/2023] [Indexed: 06/17/2023]
Abstract
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine cutaneous tumor with high metastatic potential. In rare cases, it can be associated with paraneoplastic syndromes (PNS), which result from an antitumor immunity against antigens produced by the tumor itself. Lambert-Eaton Myasthenic Syndrome (LEMS) is a neurological autoimmune PNS characterized by an impairment of the neuromuscular junction, leading to proximal muscle weakness and fatigability. Although the development of immune checkpoint inhibitors (ICI) is a breakthrough in the management of many cancers, onset or worsen of immune diseases has been described. Thereby, in patients with previous neurological PNS like LEMS, the ICI therapy for cancer may aggravate neurological symptoms and lead to irreversible impairment. We report here 2 cases of patients with metastatic MCC associated with a LEMS at the diagnosis. Both successfully received ICI therapies (anti-PDL1 avelumab and anti-PD1 pembrolizumab) without worsening of LEMS and any major immune-related adverse effects. Their neurological condition improved and disappeared concomitantly with the efficacy of immunotherapy, and we did not observe relapse of both MCC and LEMS after treatment discontinuation. Finally, we performed a complete review of the literature, which confirmed that ICI treatment could be discussed for patients with paraneoplastic LEMS, and emphasized the need for multidisciplinary management.
Collapse
Affiliation(s)
- Marion Gra
- CHU de Bordeaux, Service de Dermatologie, Bordeaux, France
| | - Anne Pham-Ledard
- CHU de Bordeaux, Service de Dermatologie, Bordeaux, France
- BRIC (BoRdeaux Institute of onCology), UMR1312, Team 5, INSERM, Univ, Bordeaux, Bordeaux, France
| | - Emilie Gerard
- CHU de Bordeaux, Service de Dermatologie, Bordeaux, France
| | - Caroline Dutriaux
- CHU de Bordeaux, Service de Dermatologie, Bordeaux, France
- BRIC (BoRdeaux Institute of onCology), UMR1312, Team 5, INSERM, Univ, Bordeaux, Bordeaux, France
| | - Marie Beylot-Barry
- CHU de Bordeaux, Service de Dermatologie, Bordeaux, France
- BRIC (BoRdeaux Institute of onCology), UMR1312, Team 5, INSERM, Univ, Bordeaux, Bordeaux, France
| | - Fanny Duval
- CHU de Bordeaux, Service de Neurologie, Bordeaux, France
| | - Louis Carla
- CHU de Bordeaux, Service de Neurologie, Bordeaux, France
| | | | - Sorilla Prey
- CHU de Bordeaux, Service de Dermatologie, Bordeaux, France
- BRIC (BoRdeaux Institute of onCology), UMR1312, Team 5, INSERM, Univ, Bordeaux, Bordeaux, France
| |
Collapse
|
8
|
Mathis S, Solé G, Damon-Perrière N, Rouanet-Larrivière M, Duval F, Prigent J, Nadal L, Péréon Y, Le Masson G. Clinical Neurology in Practice: The Tongue (Part 1). Neurologist 2023; 28:338-348. [PMID: 37639535 DOI: 10.1097/nrl.0000000000000512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/31/2023]
Abstract
BACKGROUND The tongue is an essential organ for the development of certain crucial functions, such as swallowing and language. The examination of the tongue can be very useful in neurology, as the various types of lingual alterations can lead to certain specific diagnoses, the tongue being a kind of "mirror" of some neurological function. REVIEW SUMMARY In this study, we reviewed the literature on anatomy, physiology, and the various aspects of the examination of the tongue. CONCLUSIONS Examination of the tongue should be an integral part of the clinical examination of the cranial nerves. This study aimed to demonstrate the importance of tongue motor and non-motor functions in neurological practice.
Collapse
Affiliation(s)
- Stéphane Mathis
- Department of Neurology, Muscle-Nerve
- Referral Center for Neuromuscular Diseases 'AOC'
- ALS Center
| | - Guilhem Solé
- Department of Neurology, Muscle-Nerve
- Referral Center for Neuromuscular Diseases 'AOC'
| | - Nathalie Damon-Perrière
- Department of Clinical Neurophysiology
- Department of Movement Disorders, University Hospitals of Bordeaux (CHU Bordeaux, Amélie Raba-Léon, Bordeaux
| | | | - Fanny Duval
- Department of Neurology, Muscle-Nerve
- Referral Center for Neuromuscular Diseases 'AOC'
| | | | | | - Yann Péréon
- Reference Centre for Neuromuscular Diseases 'AOC'. Filenemus, Euro-NMD, University Hospitals of Nantes (CHU Nantes), Nantes, France
| | - Gwendal Le Masson
- Department of Neurology, Muscle-Nerve
- Referral Center for Neuromuscular Diseases 'AOC'
- ALS Center
| |
Collapse
|
9
|
Mathis S, Carla L, Duval F, Nadal L, Solé G, Le Masson G. Acute peripheral neuropathy following animal envenomation: A case report and systematic review. J Neurol Sci 2022; 442:120448. [PMID: 36244096 DOI: 10.1016/j.jns.2022.120448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 09/29/2022] [Accepted: 10/01/2022] [Indexed: 10/31/2022]
Abstract
Animal envenomation in humans is usually accidental or for defensive purposes. Depending on the venom composition and administration, different reactions can be observed. After reporting the first case of acute polyradiculitis in a 57-year-old healthy male after red lionfish envenomation, we propose to analyze rare similar cases of acute neuritis after animal envenomation published in the medical literature. Including our case, we found 54 patients who developed acute peripheral neuropathy after having been stung or bitten by various animals, mainly hymenoptera (in half of the cases) but also jellyfishes, snakes, corals or nonhooked arthropods. We observed two distinct patterns of peripheral neuropathy: more than half of them were polyneuropathy while the others were focal neuropathy. The prognosis was favorable in most cases. The pathophysiological mechanism associated with these rare complications remain unknown, although some hypotheses may be proposed. A direct action of certain components of the venom, such as phospholipase-A2, could explain the focal forms of peripheral neuropathy trough toxic reactions and/or vasculitis processes. The more diffuse clinical situations could be due to an allergy-triggered immune-mediated reaction (possibly linked to a molecular mimicry mechanism between venom proteins and some myelin proteins of the peripheral nervous system), or to the action of some venom components on membrane ionic channels particularly at the node of Ranvier. Even if acute peripheral neuropathies are rare after envenomation, they may occur after envenomation from various animals, and their usually favorable prognoses should be known by neurologists.
Collapse
Affiliation(s)
- Stéphane Mathis
- Department of Neurology, Nerve-Muscle Unit, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), 2 place Amélie Raba-Léon, 33000 Bordeaux, France; ALS Center, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), 2 place Amélie Raba-Léon, 33000 Bordeaux, France; AOC Neuromuscular Reference Center, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), 2 place Amélie Raba-Léon, 33000 Bordeaux, France.
| | - Louis Carla
- Department of Neurology, Nerve-Muscle Unit, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), 2 place Amélie Raba-Léon, 33000 Bordeaux, France
| | - Fanny Duval
- Department of Neurology, Nerve-Muscle Unit, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), 2 place Amélie Raba-Léon, 33000 Bordeaux, France; AOC Neuromuscular Reference Center, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), 2 place Amélie Raba-Léon, 33000 Bordeaux, France
| | - Louis Nadal
- Department of Neurology, Nerve-Muscle Unit, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), 2 place Amélie Raba-Léon, 33000 Bordeaux, France
| | - Guilhem Solé
- Department of Neurology, Nerve-Muscle Unit, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), 2 place Amélie Raba-Léon, 33000 Bordeaux, France; AOC Neuromuscular Reference Center, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), 2 place Amélie Raba-Léon, 33000 Bordeaux, France
| | - Gwendal Le Masson
- Department of Neurology, Nerve-Muscle Unit, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), 2 place Amélie Raba-Léon, 33000 Bordeaux, France; ALS Center, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), 2 place Amélie Raba-Léon, 33000 Bordeaux, France; AOC Neuromuscular Reference Center, University Hospital (CHU) of Bordeaux (Pellegrin Hospital), 2 place Amélie Raba-Léon, 33000 Bordeaux, France
| |
Collapse
|
10
|
Redonnet-Vernhet I, Duval F, Carla L, Nadal L, Ouallet JC, Solé G, Mesli S, Guibet C, Daveluy A, Le-Masson G. À propos de 12 cas d’intoxication au protoxyde d’azote diagnostiqués au CHU de Bordeaux en 2021 : nécessité du dosage de l’homocystéine totale plasmatique, biomarqueur de la carence cellulaire en vitamine B12. Therapie 2022. [DOI: 10.1016/j.therap.2022.10.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
11
|
Dupé C, Lefeuvre C, Solé G, Behin A, Pottier C, Duval F, Carlier RY, Prigent H, Lacau-Saint-Guily J, Azzeddine A, Taouagh N, Hamroun D, Nicolas G, Laforêt P. Macroglossia: A potentially severe complication of late-onset POMPE disease. Eur J Neurol 2022; 29:2121-2128. [PMID: 35302691 DOI: 10.1111/ene.15330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2021] [Revised: 02/10/2022] [Accepted: 03/03/2022] [Indexed: 11/30/2022]
Abstract
BACKGROUND Pompe disease is a rare neuromuscular disorder caused by a deficiency of a lysosomal enzyme, acid α-glucosidase. Macroglossia is a classic clinical sign of several inherited myopathies and has also been reported to occur progressively in late-onset Pompe disease (LOPD). METHODS We describe patients with LOPD and macroglossia included in the French national Pompe disease registry. Clinical, functional, and radiological data have been collected during periodic follow-up and analyzed retrospectively. These cases have been compared with 15 previously reported cases. RESULTS 5 patients, 3 female and 2 males, from 71 to 88 years old, have been included in this study. All but one of the patients suffered from symptoms related to macroglossia before the diagnosis of Pompe disease. Three had localized tongue atrophy and one had significant localized tongue hypertrophy which led to glossectomy 10 years before diagnosis. Two patients had severe dysphagia, one of whom underwent gastrostomised for enteral nutritional support. One patient experienced the persistence of numerous sleep apneas despite nocturnal BiPAP ventilation. All our patients had dysarthria, and two required speech therapy. Four patients had a tongue hypersignal on MRI T1 sequences. CONCLUSIONS Detection of macroglossia should be part of the clinical diagnosis and follow-up of patients with LOPD, with a careful evaluation of its main consequences. Macroglossia can have severe functional impacts on speech, swallowing and sleep. Whole-body MRI with facial sections may facilitate the early diagnosis of Pompe disease with the "bright tongue sign".
Collapse
Affiliation(s)
- Charlotte Dupé
- Neurology Department, Raymond Poincaré University Hospital, Garches, APHP, France
| | - Claire Lefeuvre
- Neurology Department, Raymond Poincaré University Hospital, Garches, APHP, France.,U 1179 INSERM, Université Versailles Saint Quentin en Yvelines, Paris-Saclay, France
| | - Guilhem Solé
- Neuromuscular Reference Center, Bordeaux University Hospital (Pellegrin), University of Bordeaux, Place Amélie Raba-Léon, 33000, Bordeaux, France
| | - Anthony Behin
- Institute of Myology, Pitié Salpêtrière Hospital, Paris, France
| | | | - Fanny Duval
- Neuromuscular Reference Center, Bordeaux University Hospital (Pellegrin), University of Bordeaux, Place Amélie Raba-Léon, 33000, Bordeaux, France
| | - Robert-Yves Carlier
- U 1179 INSERM, Université Versailles Saint Quentin en Yvelines, Paris-Saclay, France.,Diagnostic and Interventional Medical imaging department, Raymond Poincaré Hospital, Garches, DMU Smart Imaging, GH Université Paris-Saclay, APHP, France.,Nord-Est-Ile-de-France Neuromuscular Reference Center, FHU PHENIX, France
| | - Hélène Prigent
- U 1179 INSERM, Université Versailles Saint Quentin en Yvelines, Paris-Saclay, France.,Physiology Department, Raymond Poincaré University Hospital, Garches, APHP, France.,Nord-Est-Ile-de-France Neuromuscular Reference Center, FHU PHENIX, France
| | - Jean Lacau-Saint-Guily
- Otolaryngology Head Neck Surgery Department, Rothschild Foundation Hospital and Sorbonne university, Paris, France
| | - Arrassi Azzeddine
- Nord-Est-Ile-de-France Neuromuscular Reference Center, FHU PHENIX, France.,Institute of Myology, Pitié Salpêtrière Hospital, Paris, France
| | - Nadjib Taouagh
- Nord-Est-Ile-de-France Neuromuscular Reference Center, FHU PHENIX, France.,Institute of Myology, Pitié Salpêtrière Hospital, Paris, France
| | - Dalil Hamroun
- CHRU de Montpellier, Direction de la Recherche et de l'Innovation, Hôpital La Colombière, Montpellier, France
| | - Guillaume Nicolas
- Neurology Department, Raymond Poincaré University Hospital, Garches, APHP, France.,U 1179 INSERM, Université Versailles Saint Quentin en Yvelines, Paris-Saclay, France
| | - Pascal Laforêt
- Neurology Department, Raymond Poincaré University Hospital, Garches, APHP, France.,U 1179 INSERM, Université Versailles Saint Quentin en Yvelines, Paris-Saclay, France
| |
Collapse
|
12
|
Soulages A, Maisonobe T, Auzou P, Petit A, Allenbach Y, Barète S, Skopinski S, Ribeiro E, Jullié ML, Lamant L, Brevet F, Soulages X, Vallat JM, Martin-Négrier ML, Solé G, Duval F, Carla L, Le Masson G, Mathis S. Peripheral neuropathy and livedoid vasculopathy. J Neurol 2022; 269:3779-3788. [PMID: 35166926 DOI: 10.1007/s00415-022-11007-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 12/24/2021] [Accepted: 02/02/2022] [Indexed: 12/01/2022]
Abstract
BACKGROUND Livedoid vasculopathy (LV) is a chronic dermatosis associated with micro-thrombosis of the vessels of the dermis, leading to ischemic lesions and painful skin ulcerations of the lower limbs. This thrombosing occlusive vasculopathy, clearly distinct from 'classical vasculitis' (not related to alteration of vessel walls), may lead to peripheral neuropathy. OBJECTIVE To clarify the main clinical, electrophysiological and pathological characteristics of peripheral neuropathy linked to LV. METHOD We presented a series of personal cases of peripheral neuropathy due to LV. We also conducted a review of the literature (since the first description of LV in 1974) using multiple combinations of keywords from 'PubMed', 'Google Scholar' and 'ScienceDirect' databases according to the 'Preferred Reporting Items for Systematic reviews and Meta-Analyses' guidelines. RESULTS We identified 16 patients (6 personal cases and 10 cases from the medical literature). Our personal cases were five females and one male, with a median age (at the onset of cutaneous signs of LV) of 38 (range 25-62). Several types of skin lesions of the lower limbs were observed. Median age at the onset of peripheral neuropathy symptoms was 48 years (range 29-66), with a main clinical and electrophysiological pattern of mononeuropathy multiplex. DISCUSSION We observed a typical pattern of peripheral neuropathy, mostly mononeuropathy multiplex, whose pathophysiology might be related to occlusions of the small vessels of the nerves, as seen in the dermis. Moreover, LV may also be associated with other types of peripheral neuropathies (sometimes of autoimmune etiology) not directly related to the skin lesions. CONCLUSION The 'ischemic form' of peripheral neuropathy linked to LV is mainly responsible for sensory disturbances (with multifocal distribution), sometimes for motor disturbances. This type of peripheral neuropathy has to be distinguished from 'classical vasculitic neuropathies' which are usually treated with antithrombotic therapies.
Collapse
Affiliation(s)
- Antoine Soulages
- Department of Neurology, Nerve-Muscle Unit, Referral Center for Neuromuscular Diseases AOC, University Hospital of Bordeaux (CHU Bordeaux, Pellegrin Hospital), Bordeaux, France
| | - Thierry Maisonobe
- Department of Clinical Neurophysiology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | - Pascal Auzou
- Department of Neurology, CHR Orléans, Orléans, France
| | - Antoine Petit
- Department of Dermatology, AP-HP, Saint-Louis Hospital, Paris, France
| | - Yves Allenbach
- Department of Internal Medicine and Clinical Immunology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | - Stéphane Barète
- Department of Dermatology, Sorbonne Université (UPMC Paris-6), Paris, France
| | - Sophie Skopinski
- Department of Vascular Medicine, University Hospital of Bordeaux (CHU Bordeaux, Saint-André Hospital), Bordeaux, France
| | - Emmanuel Ribeiro
- Department of Internal Medicine and Tropical Diseases, University Hospital of Bordeaux (CHU Bordeaux, Saint-André Hospital), Bordeaux, France
| | - Marie-Laure Jullié
- Department of Pathology, University Hospital of Bordeaux (CHU Bordeaux, Haut-Lévêque Hospital), Pessac, France
| | - Laurence Lamant
- Department of Pathology, Institut Universitaire du Cancer de Toulouse, Oncopole (IUC-T), Toulouse, France
| | | | - Xavier Soulages
- Neurology Office, 23 Boulevard de la République, Rodez, France
| | - Jean-Michel Vallat
- Department of Neurology, University Hospital of Limoges (Dupuytren Hospital), Limoges, France
| | - Marie-Laure Martin-Négrier
- Department of Pathology, University Hospital of Bordeaux (CHU Bordeaux, Pellegrin Hospital), Bordeaux, France
| | - Guilhem Solé
- Department of Neurology, Nerve-Muscle Unit, Referral Center for Neuromuscular Diseases AOC, University Hospital of Bordeaux (CHU Bordeaux, Pellegrin Hospital), Bordeaux, France
| | - Fanny Duval
- Department of Neurology, Nerve-Muscle Unit, Referral Center for Neuromuscular Diseases AOC, University Hospital of Bordeaux (CHU Bordeaux, Pellegrin Hospital), Bordeaux, France
| | - Louis Carla
- Department of Neurology, Nerve-Muscle Unit, Referral Center for Neuromuscular Diseases AOC, University Hospital of Bordeaux (CHU Bordeaux, Pellegrin Hospital), Bordeaux, France
| | - Gwendal Le Masson
- Department of Neurology, Nerve-Muscle Unit, Referral Center for Neuromuscular Diseases AOC, University Hospital of Bordeaux (CHU Bordeaux, Pellegrin Hospital), Bordeaux, France
| | - Stéphane Mathis
- Department of Neurology, Nerve-Muscle Unit, Referral Center for Neuromuscular Diseases AOC, University Hospital of Bordeaux (CHU Bordeaux, Pellegrin Hospital), Bordeaux, France.
| |
Collapse
|
13
|
Soulages A, Sibon I, Vallat JM, Ellie E, Bourdain F, Duval F, Carla L, Martin-Négrier ML, Solé G, Laurent C, Monnier A, Le Masson G, Mathis S. Neurologic manifestations of giant cell arteritis. J Neurol 2022; 269:3430-3442. [DOI: 10.1007/s00415-022-10991-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 01/21/2022] [Accepted: 01/21/2022] [Indexed: 10/19/2022]
|
14
|
Dumonceau AG, Ameli R, Rogemond V, Ruiz A, Joubert B, Muñiz-Castrillo S, Vogrig A, Picard G, Ambati A, Benaiteau M, Rulquin F, Ciron J, Deiva K, de Broucker T, Kremer L, Kerschen P, Sellal F, Bouldoires B, Genet R, Biberon J, Bigot A, Duval F, Issa N, Rusu EC, Goudot M, Dutray A, Devoize JL, Hopes L, Kaminsky AL, Philbert M, Chanson E, Leblanc A, Morvan E, Andriuta D, Diraison P, Mirebeau G, Derollez C, Bourg V, Bodard Q, Fort C, Grigorashvili-Coin I, Rieul G, Molinier-Tiganas D, Bonnan M, Tchoumi T, Honnorat J, Marignier R. Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study. Neurology 2021; 98:e653-e668. [PMID: 34799461 PMCID: PMC8829963 DOI: 10.1212/wnl.0000000000013087] [Citation(s) in RCA: 43] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Accepted: 11/12/2021] [Indexed: 11/21/2022] Open
Abstract
Background and Objectives To report the clinical, biological, and imaging features and clinical course of a French cohort of patients with glial fibrillary acidic protein (GFAP) autoantibodies. Methods We retrospectively included all patients who tested positive for GFAP antibodies in the CSF by immunohistochemistry and confirmed by cell-based assay using cells expressing human GFAPα since 2017 from 2 French referral centers. Results We identified 46 patients with GFAP antibodies. Median age at onset was 43 years, and 65% were men. Infectious prodromal symptoms were found in 82%. Other autoimmune diseases were found in 22% of patients, and coexisting neural autoantibodies in 11%. Tumors were present in 24%, and T-cell dysfunction in 23%. The most frequent presentation was subacute meningoencephalitis (85%), with cerebellar dysfunction in 57% of cases. Other clinical presentations included myelitis (30%) and visual (35%) and peripheral nervous system involvement (24%). MRI showed perivascular radial enhancement in 32%, periventricular T2 hyperintensity in 41%, brainstem involvement in 31%, leptomeningeal enhancement in 26%, and reversible splenial lesions in 4 cases. A total of 33 of 40 patients had a monophasic course, associated with a good outcome at last follow-up (Rankin Score ≤2: 89%), despite a severe clinical presentation. Adult and pediatric features are similar. Thirty-two patients were treated with immunotherapy. A total of 11/22 patients showed negative conversion of GFAP antibodies. Discussion GFAP autoimmunity is mainly associated with acute/subacute meningoencephalomyelitis with prodromal symptoms, for which tumors and T-cell dysfunction are frequent triggers. The majority of patients followed a monophasic course with a good outcome.
Collapse
Affiliation(s)
- Alice Gravier Dumonceau
- Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, and Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677 Lyon/Bron, France
| | - Roxana Ameli
- Service d'imagerie médicale, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677 Lyon/Bron, France
| | - Veronique Rogemond
- Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677 Lyon/Bron, France ; Institut NeuroMyoGène, INSERM 1217 et CNRS UMR5310, 69008 Lyon, France ; Université Claude Bernard Lyon 1, Faculté de médecine Lyon Est, 69008 Lyon, France
| | - Anne Ruiz
- Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, 69003 Lyon, France
| | - Bastien Joubert
- Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677 Lyon/Bron, France ; Institut NeuroMyoGène, INSERM 1217 et CNRS UMR5310, 69008 Lyon, France ; Université Claude Bernard Lyon 1, Faculté de médecine Lyon Est, 69008 Lyon, France
| | - Sergio Muñiz-Castrillo
- Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677 Lyon/Bron, France ; Institut NeuroMyoGène, INSERM 1217 et CNRS UMR5310, 69008 Lyon, France ; Université Claude Bernard Lyon 1, Faculté de médecine Lyon Est, 69008 Lyon, France
| | - Alberto Vogrig
- Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677 Lyon/Bron, France ; Institut NeuroMyoGène, INSERM 1217 et CNRS UMR5310, 69008 Lyon, France ; Université Claude Bernard Lyon 1, Faculté de médecine Lyon Est, 69008 Lyon, France
| | - Geraldine Picard
- Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677 Lyon/Bron, France ; Institut NeuroMyoGène, INSERM 1217 et CNRS UMR5310, 69008 Lyon, France ; Université Claude Bernard Lyon 1, Faculté de médecine Lyon Est, 69008 Lyon, France
| | - Aditya Ambati
- Stanford University Center for Sleep Sciences and Medecine, Palo Alto, CA, USA
| | - Marie Benaiteau
- Service de neurologie cognitive, épilepsie, sommeil et mouvements anormaux, Hôpital Pierre-Paul Riquet, Hôpitaux de Toulouse, 31059 Toulouse, France
| | - Florence Rulquin
- Service de neurologie inflammatoire et neuro-oncologie, Hôpital Pierre-Paul Riquet, Hôpitaux de Toulouse, 31059 Toulouse, France
| | - Jonathan Ciron
- Service de neurologie inflammatoire et neuro-oncologie, Hôpital Pierre-Paul Riquet, Hôpitaux de Toulouse, 31059 Toulouse, France
| | - Kumaran Deiva
- Service de neuropédiatrie, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, 94270 Le Kremlin-Bicêtre, France
| | - Thomas de Broucker
- Service de neurologie, Hôpital Delafontaine, Centre Hospitalier de Saint-Denis, 93205 Saint-Denis, France
| | - Laurent Kremer
- Service de neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, 67200 Strasbourg, France
| | - Philippe Kerschen
- Service de neurologie, Centre Hospitalier de Luxembourg, 1210 Luxembourg, Luxembourg
| | - François Sellal
- Service de neurologie, Hôpitaux Civils de Colmar, 68000 Colmar, France ; Unité INSERM U-1118, Faculté de Médecine, Université de Strasbourg
| | - Bastien Bouldoires
- Service de médecine interne, Hôpitaux civils de Colmar, 68000 Colmar, France
| | - Roxana Genet
- Service de médecine interne, Hôpital d'Instruction des Armées Legouest, 57000 Metz, France
| | - Jonathan Biberon
- Service de neurologie, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France
| | - Adrien Bigot
- Service de médecine interne et immunologie clinique, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France
| | - Fanny Duval
- Service de neurologie et maladies neuromusculaires, Groupe Hospitalier Pellegrin, Hôpitaux de Bordeaux, 33000 Bordeaux, France
| | - Nahema Issa
- Service de médecine intensive et réanimation, Hôpital Saint André, 33000 Bordeaux, France
| | - Elena-Camelia Rusu
- Service de neurologie, Hôpital Sainte Musse, Centre Hospitalier Intercommunal de Toulon, 83056 Toulon, France
| | - Mathilde Goudot
- Service de neurologie, Hôpital Emile Muller, 68100 Mulhouse, France
| | - Anais Dutray
- Service de neurologie, Centre Hospitalier de Perpignan, 66046 Perpignan, France
| | - Jean Louis Devoize
- Pôle Cardio-vasculaire et métabolique, Centre hospitalier de Cayenne, 97300 Cayenne, France
| | - Lucie Hopes
- Service de neurologie, Hôpital Central, CHRU Nancy, 54035 Nancy, France
| | - Anne-Laure Kaminsky
- Service de neurologie, CHU de Saint-Etienne, 42270 Saint-Priest-en-Jarez, France
| | - Marion Philbert
- Service de neuropédiatrie, Site Mère Enfant, CHU Martinique, 97200 Fort-de-France, France
| | - Eve Chanson
- Service de neurologie, CHU Gabriel-Montpied, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France
| | - Amelie Leblanc
- Service de neurologie, Hôpital d'Instruction des Armées Clermont-Tonnerre, 29240 Brest, France
| | - Erwan Morvan
- Service de neurologie, Hôpital Fondation Adolphe de Rothschild, 75019 Paris, France
| | - Daniela Andriuta
- Service de Neurologie et Laboratoire de Neurosciences Fonctionnelles et Pathologies, Centre Hospitalier universitaire d'Amiens et Université de Picardie Jules Verne, Amiens, France
| | - Philippe Diraison
- Service de neurologie, Hôpital Laënnec, Centre Hospitalier de Cornouaille, 29107 Quimper, France
| | - Gabriel Mirebeau
- Service de neurologie, Centre Hospitalier Universitaire de La Réunion, 97410 Saint Pierre, France
| | - Celine Derollez
- Service de neurologie, Hôpital Roger Salengro, Centre Hospitalier Universitaire de Lille, 59037 Lille, France
| | - Veronique Bourg
- Service de neurologie, Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice, 06000 Nice, France
| | - Quentin Bodard
- Service de médecine interne et maladies infectieuses, Centre Hospitalier d'Angoulême, 16959 Angoulême, France
| | - Clementine Fort
- Service de neurologie pédiatrique, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, 69677 Lyon/Bron, France
| | | | - Guillaume Rieul
- Service de réanimation, Centre Hospitalier de Saint-Brieuc, 22027 Saint-Brieuc, France
| | - Daniela Molinier-Tiganas
- Service de médecine polyvalente et de médecine interne, Centre Hospitalier Le Mans, 72037 Le Mans, France
| | - Mickaël Bonnan
- Service de neurologie, Centre Hospitalier de Pau, 64046 Pau, France
| | - Thierry Tchoumi
- Service de neurologie/UNV, Centre Hospitalier de Saintonge, 17100 Saintes, France
| | - Jérôme Honnorat
- Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677 Lyon/Bron, France ; Institut NeuroMyoGène, INSERM 1217 et CNRS UMR5310, 69008 Lyon, France ; Université Claude Bernard Lyon 1, Faculté de médecine Lyon Est, 69008 Lyon, France
| | - Romain Marignier
- Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, and Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677 Lyon/Bron, France.,Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, 69003 Lyon, France
| |
Collapse
|
15
|
Zhong W, Perre P, Duval F, Lemaire J. A predictive model of organic acids separation by chromatography with strong anionic resins in sulfate form. J Chromatogr A 2021; 1661:462671. [PMID: 34890853 DOI: 10.1016/j.chroma.2021.462671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 11/01/2021] [Accepted: 11/02/2021] [Indexed: 10/19/2022]
Abstract
Organic acids commonly have quite symmetrical chromatography profiles at low pH (< 1.5) with strong anionic resins, but a significant tailing can be observed with succinic and citric acids. Classical adsorption models, like the Langmuir model, fail to predict this behavior, which can have a major influence on mean retention times and profile shapes, therefore on chromatography performances. A new retention model was developed to better predict organic acid separation with strong anionic resin. This model combines a refined Langmuir adsorption model and an ion-exchange model. Organic acid adsorption is assumed to be due to hydrogen bonding with sulfate and hydrogen sulfate counter-anions on the resin. The adsorption capacity depends mostly on molecular size: up to sixteen formic acid molecules could be adsorbed per counter-anions, meanwhile only two succinic acid or one citric acid molecules could be adsorbed. This adsorption model was then embedded in a generic and accurate modeling approach (continuous column with mass balance equations solved by the conservation element/solution element (CE/SE) method). All parameters of this column model were identified by fitting the simulation to experimental results (equilibrium curves and pulse tests). Then, the column model was validated with original experimental results from a binary mixture pulse test (formic and succinic acids). Results show that simulations are much more predictive for multi-component pulse tests, both in terms of profile shape and retention time, which cannot be captured without considering ion-exchange.
Collapse
Affiliation(s)
- Wuyang Zhong
- Laboratoire de Génie des Procédés et Matériaux, SFR Condorcet FR CNRS 3417, Université Paris-Saclay, CentraleSupélec, Center Européen de Biotechnologie et de Bioéconomie, 3 rue qdes Rouges Terres, Pomacle 51110, France
| | - Patrick Perre
- Laboratoire de Génie des Procédés et Matériaux, SFR Condorcet FR CNRS 3417, Université Paris-Saclay, CentraleSupélec, Center Européen de Biotechnologie et de Bioéconomie, 3 rue qdes Rouges Terres, Pomacle 51110, France
| | - Fanny Duval
- Laboratoire de Génie des Procédés et Matériaux, SFR Condorcet FR CNRS 3417, Université Paris-Saclay, CentraleSupélec, Center Européen de Biotechnologie et de Bioéconomie, 3 rue qdes Rouges Terres, Pomacle 51110, France
| | - Julien Lemaire
- Laboratoire de Génie des Procédés et Matériaux, SFR Condorcet FR CNRS 3417, Université Paris-Saclay, CentraleSupélec, Center Européen de Biotechnologie et de Bioéconomie, 3 rue qdes Rouges Terres, Pomacle 51110, France.
| |
Collapse
|
16
|
Galtier J, Duval F, Machelart I, Greib C, Lazaro E, Pellegrin J, Viallard J, Tour RP, Rivière E. Myasthenia gravis and paroxysmal nocturnal hemoglobinuria after thymectomy: A rare association. eJHaem 2021; 2:834-837. [PMID: 35845222 PMCID: PMC9176050 DOI: 10.1002/jha2.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Revised: 05/20/2021] [Accepted: 05/23/2021] [Indexed: 11/08/2022]
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is a very rare clonal autoimmune disease manifesting with hemolysis, thrombosis, or bone marrow failure. We present an atypical association of myasthenia gravis, aplastic anemia, and PNH occurring years after thymectomy. While this association might be extremely rare, it may not be coincidental as there is a common pathophysiology between PNH and aplastic anemia, with the latter reported in several thymoma/thymectomy cases. Eculizumab was introduced with good efficacy and without safety concern in our patient, leading to long‐term control of PNH without worsening of myasthenia gravis.
Collapse
Affiliation(s)
- Jean Galtier
- Hematology Department Haut‐Leveque Hospital University Hospital Center of Bordeaux Pessac France
| | - Fanny Duval
- Neurology Department Pellegrin Hospital University Hospital Center of Bordeaux Bordeaux France
| | - Irène Machelart
- Internal Medicine and Infectious Diseases Haut‐Leveque Hospital University Hospital Center of Bordeaux Pessac France
| | - Carine Greib
- Internal Medicine and Infectious Diseases Haut‐Leveque Hospital University Hospital Center of Bordeaux Pessac France
| | - Estibaliz Lazaro
- Internal Medicine and Infectious Diseases Haut‐Leveque Hospital University Hospital Center of Bordeaux Pessac France
| | - Jean‐Luc Pellegrin
- Internal Medicine and Infectious Diseases Haut‐Leveque Hospital University Hospital Center of Bordeaux Pessac France
| | - Jean‐François Viallard
- Internal Medicine and Infectious Diseases Haut‐Leveque Hospital University Hospital Center of Bordeaux Pessac France
- INSERM U1034 Pessac Cedex France
| | - Regis Peffault Tour
- Service d'Hématologie Greffe Centre de référence des aplasies médullaires acquises et constitutionnelles Hôpital Saint Louis AP‐HP Paris France
| | - Etienne Rivière
- Internal Medicine and Infectious Diseases Haut‐Leveque Hospital University Hospital Center of Bordeaux Pessac France
- INSERM U1034 Pessac Cedex France
| |
Collapse
|
17
|
Montes G, Duval F, Eldani C, Amico S, Gérard E, Dutriaux C, Herran C, Poullenot F, Sole G, Carla L, Guerin C, Célerier P, Prey S. Esophageal Achalasia Induced by Ipilimumab and Nivolumab Combination: A Rare Neurological Manifestation of Immune-related Autonomic Neuropathy. J Immunother 2021; 44:348-350. [PMID: 34166302 DOI: 10.1097/cji.0000000000000381] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Accepted: 04/19/2021] [Indexed: 11/26/2022]
Abstract
Immunotherapy with immune checkpoint inhibitors (ICIs) has improved the prognosis of many cancers; a combination of nivolumab (anti-programmed cell death protein 1) and ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4) is approved as first-line therapy for advanced melanoma, with objective responses obtained in more than half of patients. However, this combination is associated with a high rate of immune-related adverse events, which are often severe and multiple. Neurological immune-related adverse events are rare but feared because they can be life-threatening, their diagnosis and management are challenging, and patients can have irreversible sequelae. We reported a case of a young patient treated by nivolumab and ipilimumab combination for metastatic melanoma. Severe dysphagia with regurgitations, major weight loss, uveitis, and vitiligo occurred after 3 infusions of nivolumab and ipilimumab. Magnetic resonance imaging and positron emission tomography scan showed complete remission of melanoma. The endoscopic examination did not find any digestive toxicity. Esophageal manometry revealed achalasia. This was associated with mydriasis, pathologic deep breath test, and alteration of the cutaneous sympathetic response on electromyogram, which was consistent with autonomic neuropathy. This rare etiology of atypical vomiting under ICI should be known by prescribers, as ICI prescription is widening in many new cancers.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | - Sorilla Prey
- Dermatology Department
- University of Bordeaux, Inserm U-1035
| |
Collapse
|
18
|
Pisella LI, Fernandes S, Solé G, Stojkovic T, Tard C, Chanson JB, Bouhour F, Salort-Campana E, Beaudonnet G, Debergé L, Duval F, Grapperon AM, Masingue M, Nadaj-Pakleza A, Péréon Y, Audic F, Behin A, Friedman D, Magot A, Noury JB, Souvannanorath S, Wahbi K, Antoine JC, Bigaut K, Camdessanché JP, Cintas P, Debs R, Espil-Taris C, Kremer L, Kuntzer T, Laforêt P, Laugel V, Mallaret M, Michaud M, Nollet S, Svahn J, Vicart S, Villar-Quiles RN, Desguerre I, Adams D, Segovia-Kueny S, Merret G, Hammouda E, Molon A, Attarian S. A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases. Orphanet J Rare Dis 2021; 16:450. [PMID: 34702344 PMCID: PMC8547719 DOI: 10.1186/s13023-021-02090-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Accepted: 10/17/2021] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Due to their health condition, patients with neuromuscular diseases (NMD) are at greater risk of developing serious complications with COVID-19. The objective of this study was to analyze the prevalence of COVID-19 among NMD patients and the risk factors for its impact and severity during the first wave of the pandemic. Clinical data were collected from NMD-COVID-19 patients, between March 25, 2020 and May 11, 2020 in an anonymous survey carried out by expert physicians from the French Health Care Network Filnemus. RESULTS Physicians reported 84 patients, including: 34 with myasthenia gravis, 27 with myopathy and 23 with neuropathy. COVID-19 had no effect on NMD for 48 (58%) patients and 48 (58%) patients developed low COVID-19 severity. COVID-19 caused the death of 9 (11%) NMD patients. Diabetic patients were at greater risk of dying. Patients with diabetes, hypertension or severe forms of NMD had a higher risk of developing a moderate or severe form of COVID-19. In our cohort, corticosteroids and other immunosuppressants were not significantly associated with higher COVID-19 severity for acquired NMD. CONCLUSION During this period, a small percentage of French NMD patients was affected by COVID-19 compared to the general French population and COVID-19 had a limited short-term effect on them. Diabetes, hypertension and a severe degree of NMD were identified as risk factors of unfavorable outcome following COVID-19. Conversely, in our cohort of patients with acquired NMD, corticosteroids or other immunosuppressants did not appear to be risk factors for more severe COVID-19.
Collapse
Affiliation(s)
| | - Sara Fernandes
- Department of Epidemiology and Health Economics, AP-HM, Marseille, France
| | - Guilhem Solé
- Department of Neurology and Neuromuscular Disorders, Reference Center for Neuromuscular Disorders AOC, University Hospitals of Bordeaux (Pellegrin University Hospital), place Amélie-Raba-Léon, 33076, Bordeaux, France
| | - Tanya Stojkovic
- Reference Center for Neuromuscular Disorders Nord/Est/Île-de-France, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Inserm UMR_S 974, Paris, France
| | - Céline Tard
- CHU de Lille, Inserm U1171, Reference Center for Neuromuscular Disorders Nord/Est/Île-de-France, Lille, France
| | - Jean-Baptiste Chanson
- Neurology Department, Reference Center for Neuromuscular Diseases 'Nord-Est-Ile de France', University Hospitals of Strasbourg, Strasbourg, France
| | - Françoise Bouhour
- ENMG Unit, Reference Center for Neuromuscular Diseases, University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer), Lyon, France
| | - Emmanuelle Salort-Campana
- Filnemus, AP-HM, Marseille, France
- Reference Center for Neuromuscular Diseases and ALS, Timone University Hospital, Aix-Marseille University, ERN-Center, Marseille, France
| | - Guillemette Beaudonnet
- Clinical Neurophysiology Unit, Reference Center for Neuromuscular Disease, University Hospital of Bicetre, Le Kremlin Bicêtre, France
| | - Louise Debergé
- Department of Neurology and Neuromuscular Disorders, Reference Center for Neuromuscular Disorders AOC, University Hospitals of Bordeaux (Pellegrin University Hospital), place Amélie-Raba-Léon, 33076, Bordeaux, France
| | - Fanny Duval
- Department of Neurology and Neuromuscular Disorders, Reference Center for Neuromuscular Disorders AOC, University Hospitals of Bordeaux (Pellegrin University Hospital), place Amélie-Raba-Léon, 33076, Bordeaux, France
| | - Aude-Marie Grapperon
- Reference Center for Neuromuscular Diseases and ALS, Timone University Hospital, Aix-Marseille University, ERN-Center, Marseille, France
| | - Marion Masingue
- Reference Center for Neuromuscular Disorders Nord/Est/Île-de-France, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Inserm UMR_S 974, Paris, France
| | - Aleksandra Nadaj-Pakleza
- Neurology Department, Reference Center for Neuromuscular Diseases 'Nord-Est-Ile de France', University Hospitals of Strasbourg, Strasbourg, France
| | - Yann Péréon
- Reference Center for Neuromuscular Diseases, Filnemus, ERN Euro-NMD, CHU Nantes, Nantes, France
| | - Frédérique Audic
- Reference Center for Neuromuscular Diseases, Neuropediatric Unit Timone University Hospital, Marseille, France
| | - Anthony Behin
- Reference Center for Neuromuscular Disorders Nord/Est/Île-de-France, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Inserm UMR_S 974, Paris, France
| | - Diane Friedman
- Neurology Department, Nord/Est/Île-de-France Neuromuscular Reference Center, Raymond-Poincaré Teaching Hospital, AP-HP, Garches, France
| | - Armelle Magot
- Reference Center for Neuromuscular Diseases, Filnemus, ERN Euro-NMD, CHU Nantes, Nantes, France
| | - Jean-Baptiste Noury
- Reference Center for Neuromuscular Diseases AOC, University Hospital of Brest, Brest, France
| | - Sarah Souvannanorath
- Reference Center for Neuromuscular Diseases, Henri Mondor University Hospital, Assistance Publique - Hôpitaux de Paris, Créteil, France
| | - Karim Wahbi
- AP-HP, Cochin Hospital, Cardiology Department, FILNEMUS, Reference Center for Neuromuscular Diseases Nord/Est/Île-de-France, Paris-Descartes, Sorbonne Paris Cité University, 75006, Paris, France
- INSERM Unit 970, Paris Cardiovascular Research Center (PARCC), Paris, France
| | - Jean-Christophe Antoine
- Department of Neurology, Reference Center for Neuromuscular Diseases, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - Kévin Bigaut
- Neurology Department, Reference Center for Neuromuscular Diseases 'Nord-Est-Ile de France', University Hospitals of Strasbourg, Strasbourg, France
| | - Jean-Philippe Camdessanché
- Department of Neurology, Reference Center for Neuromuscular Diseases, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - Pascal Cintas
- Department of Neurology, Reference Center for Neuromuscular Diseases, University Hospitals of Toulouse (Purpan Hospital), Toulouse, France
| | - Rabab Debs
- Clinical Neurophysiology Department, Hôpital Pitié-Salpêtrière, APHP Paris VI Université, Paris, France
| | - Caroline Espil-Taris
- Department of Pediatric Neurology, Neuromuscular Center, CHU Bordeaux, Bordeaux, France
| | - Laurent Kremer
- Neurology Department, Reference Center for Neuromuscular Diseases 'Nord-Est-Ile de France', University Hospitals of Strasbourg, Strasbourg, France
| | - Thierry Kuntzer
- Nerve-Muscle Unit, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland
| | - Pascal Laforêt
- Neurology Department, Nord/Est/Île-de-France Neuromuscular Reference Center, Raymond-Poincaré Teaching Hospital, AP-HP, Garches, France
- INSERM U1179, END-ICAP, Versailles-Saint-Quentin-en-Yvelines University, Université Paris Saclay, Montigny-le-Bretonneux, France
| | - Vincent Laugel
- Department of Pediatrics, Strasbourg University Hospital, Strasbourg Cedex, France
| | - Martial Mallaret
- Department of Neurology, Competence Center for Neuromuscular Diseases, University Hospital Centre Grenoble Alpes, CS 10217, 38043, Grenoble Cedex 9, France
| | - Maud Michaud
- Department of Neurology, Nancy University Hospital, Nancy, France
| | - Sylvain Nollet
- Clinical Neurology-Electrophysiology Department, University Hospital (CHRU) Besançon, Besançon, France
| | - Juliette Svahn
- ENMG Unit, Reference Center for Neuromuscular Diseases, University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer), Lyon, France
| | - Savine Vicart
- Reference Center for Neuromuscular Disorders Nord/Est/Île-de-France, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Inserm UMR_S 974, Paris, France
| | - Rocio Nur Villar-Quiles
- Reference Center for Neuromuscular Disorders Nord/Est/Île-de-France, Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Inserm UMR_S 974, Paris, France
| | - Isabelle Desguerre
- Reference Center for Neuromuscular Disorders Nord/Est/Île-de-France, Pediatric Neurology Department, Necker-Enfants-Malades Hospital, AP-HP, Paris, France
| | - David Adams
- Department of Neurology, University Hospital of Bicêtre, Le Kremlin-Bicêtre, France
| | | | | | | | | | - Shahram Attarian
- Filnemus, AP-HM, Marseille, France.
- Reference Center for Neuromuscular Diseases and ALS, Timone University Hospital, Aix-Marseille University, ERN-Center, Marseille, France.
| |
Collapse
|
19
|
Aliberti R, Ambrosino F, Ammendola R, Angelucci B, Antonelli A, Anzivino G, Arcidiacono R, Bache T, Baeva A, Baigarashev D, Barbanera M, Bernhard J, Biagioni A, Bician L, Biino C, Bizzeti A, Blazek T, Bloch-Devaux B, Bonaiuto V, Boretto M, Bragadireanu AM, Britton D, Brizioli F, Brunetti MB, Bryman D, Bucci F, Capussela T, Carmignani J, Ceccucci A, Cenci P, Cerny V, Cerri C, Checcucci B, Conovaloff A, Cooper P, Cortina Gil E, Corvino M, Costantini F, Cotta Ramusino A, Coward D, D'Agostini G, Dainton JB, Dalpiaz P, Danielsson H, De Simone N, Di Filippo D, Di Lella L, Doble N, Duk V, Duval F, Döbrich B, Emelyanov D, Engelfried J, Enik T, Estrada-Tristan N, Falaleev V, Fantechi R, Fascianelli V, Federici L, Fedotov S, Filippi A, Fiorini M, Fry JR, Fu J, Fucci A, Fulton L, Gamberini E, Gatignon L, Georgiev G, Ghinescu SA, Gianoli A, Giorgi M, Giudici S, Gonnella F, Goudzovski E, Graham C, Guida R, Gushchin E, Hahn F, Heath H, Henshaw J, Holzer EB, Husek T, Hutanu OE, Hutchcroft D, Iacobuzio L, Iacopini E, Imbergamo E, Jenninger B, Jerhot J, Jones RWL, Kampf K, Kekelidze V, Kholodenko S, Khoriauli G, Khotyantsev A, Kleimenova A, Korotkova A, Koval M, Kozhuharov V, Kucerova Z, Kudenko Y, Kunze J, Kurochka V, Kurshetsov V, Lamanna G, Lanfranchi G, Lari E, Latino G, Laycock P, Lazzeroni C, Lehmann Miotto G, Lenti M, Leonardi E, Lichard P, Litov L, Lollini R, Lomidze D, Lonardo A, Lubrano P, Lupi M, Lurkin N, Madigozhin D, Mannelli I, Mapelli A, Marchetto F, Marchevski R, Martellotti S, Massarotti P, Massri K, Maurice E, Medvedeva M, Mefodev A, Menichetti E, Migliore E, Minucci E, Mirra M, Misheva M, Molokanova N, Moulson M, Movchan S, Napolitano M, Neri I, Newson F, Norton A, Noy M, Numao T, Obraztsov V, Ostankov A, Padolski S, Page R, Palladino V, Parenti A, Parkinson C, Pedreschi E, Pepe M, Perrin-Terrin M, Peruzzo L, Petrov P, Petrov Y, Petrucci F, Piandani R, Piccini M, Pinzino J, Polenkevich I, Pontisso L, Potrebenikov Y, Protopopescu D, Raggi M, Romano A, Rubin P, Ruggiero G, Ryjov V, Salamon A, Santoni C, Saracino G, Sargeni F, Schuchmann S, Semenov V, Sergi A, Shaikhiev A, Shkarovskiy S, Soldi D, Sozzi M, Spadaro T, Spinella F, Sturgess A, Sugonyaev V, Swallow J, Trilov S, Valente P, Velghe B, Venditti S, Vicini P, Volpe R, Vormstein M, Wahl H, Wanke R, Wrona B, Yushchenko O, Zamkovsky M, Zinchenko A. Search for Lepton Number and Flavor Violation in K^{+} and π^{0} Decays. Phys Rev Lett 2021; 127:131802. [PMID: 34623867 DOI: 10.1103/physrevlett.127.131802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Accepted: 07/22/2021] [Indexed: 06/13/2023]
Abstract
Searches for the lepton number violating K^{+}→π^{-}μ^{+}e^{+} decay and the lepton flavor violating K^{+}→π^{+}μ^{-}e^{+} and π^{0}→μ^{-}e^{+} decays are reported using data collected by the NA62 experiment at CERN in 2017-2018. No evidence for these decays is found and upper limits of the branching ratios are obtained at 90% confidence level: B(K^{+}→π^{-}μ^{+}e^{+})<4.2×10^{-11}, B(K^{+}→π^{+}μ^{-}e^{+})<6.6×10^{-11} and B(π^{0}→μ^{-}e^{+})<3.2×10^{-10}. These results improve by 1 order of magnitude over previous results for these decay modes.
Collapse
Affiliation(s)
- R Aliberti
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - F Ambrosino
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - R Ammendola
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - B Angelucci
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - A Antonelli
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - G Anzivino
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - R Arcidiacono
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - T Bache
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - A Baeva
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - D Baigarashev
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Barbanera
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - J Bernhard
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - A Biagioni
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - L Bician
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - C Biino
- INFN, Sezione di Torino, I-10125 Torino, Italy
| | - A Bizzeti
- INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - T Blazek
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - B Bloch-Devaux
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - V Bonaiuto
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - M Boretto
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - A M Bragadireanu
- Horia Hulubei National Institute of Physics for R&D in Physics and Nuclear Engineering, 077125 Bucharest-Magurele, Romania
| | - D Britton
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - F Brizioli
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M B Brunetti
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - D Bryman
- University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
| | - F Bucci
- INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - T Capussela
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - J Carmignani
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - A Ceccucci
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - P Cenci
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - V Cerny
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - C Cerri
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - B Checcucci
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - A Conovaloff
- George Mason University, Fairfax, Virginia 22030, USA
| | - P Cooper
- George Mason University, Fairfax, Virginia 22030, USA
| | - E Cortina Gil
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - M Corvino
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - F Costantini
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | | | - D Coward
- George Mason University, Fairfax, Virginia 22030, USA
| | - G D'Agostini
- Dipartimento di Fisica, Sapienza Università di Roma e INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - J B Dainton
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - P Dalpiaz
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - H Danielsson
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - N De Simone
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - D Di Filippo
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - L Di Lella
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - N Doble
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - V Duk
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - F Duval
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - B Döbrich
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - D Emelyanov
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - J Engelfried
- Instituto de Física, Universidad Autónoma de San Luis Potosí, 78240 San Luis Potosí, Mexico
| | - T Enik
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - N Estrada-Tristan
- Instituto de Física, Universidad Autónoma de San Luis Potosí, 78240 San Luis Potosí, Mexico
| | - V Falaleev
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - R Fantechi
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - V Fascianelli
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - L Federici
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - S Fedotov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - A Filippi
- INFN, Sezione di Torino, I-10125 Torino, Italy
| | - M Fiorini
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - J R Fry
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - J Fu
- University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
| | - A Fucci
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - L Fulton
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - E Gamberini
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - L Gatignon
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - G Georgiev
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S A Ghinescu
- Horia Hulubei National Institute of Physics for R&D in Physics and Nuclear Engineering, 077125 Bucharest-Magurele, Romania
| | - A Gianoli
- INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - M Giorgi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - S Giudici
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - F Gonnella
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E Goudzovski
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - C Graham
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - R Guida
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - E Gushchin
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - F Hahn
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - H Heath
- University of Bristol, Bristol BS8 1TH, United Kingdom
| | - J Henshaw
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E B Holzer
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - T Husek
- Charles University, 116 36 Prague 1, Czech Republic
| | - O E Hutanu
- Horia Hulubei National Institute of Physics for R&D in Physics and Nuclear Engineering, 077125 Bucharest-Magurele, Romania
| | - D Hutchcroft
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - L Iacobuzio
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E Iacopini
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - E Imbergamo
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - B Jenninger
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - J Jerhot
- Charles University, 116 36 Prague 1, Czech Republic
| | - R W L Jones
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - K Kampf
- Charles University, 116 36 Prague 1, Czech Republic
| | - V Kekelidze
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - S Kholodenko
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - G Khoriauli
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - A Khotyantsev
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - A Kleimenova
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - A Korotkova
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Koval
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - V Kozhuharov
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - Z Kucerova
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - Y Kudenko
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - J Kunze
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - V Kurochka
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - V Kurshetsov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - G Lamanna
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - G Lanfranchi
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - E Lari
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - G Latino
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - P Laycock
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - C Lazzeroni
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - G Lehmann Miotto
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - M Lenti
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - E Leonardi
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - P Lichard
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - L Litov
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - R Lollini
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - D Lomidze
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - A Lonardo
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - P Lubrano
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M Lupi
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - N Lurkin
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - D Madigozhin
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - I Mannelli
- Scuola Normale Superiore e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - A Mapelli
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - F Marchetto
- INFN, Sezione di Torino, I-10125 Torino, Italy
| | - R Marchevski
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - S Martellotti
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - P Massarotti
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - K Massri
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - E Maurice
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - M Medvedeva
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - A Mefodev
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - E Menichetti
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - E Migliore
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - E Minucci
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - M Mirra
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - M Misheva
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - N Molokanova
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Moulson
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S Movchan
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Napolitano
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - I Neri
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - F Newson
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - A Norton
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - M Noy
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - T Numao
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - V Obraztsov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - A Ostankov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - S Padolski
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - R Page
- University of Bristol, Bristol BS8 1TH, United Kingdom
| | - V Palladino
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - A Parenti
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - C Parkinson
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E Pedreschi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - M Pepe
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M Perrin-Terrin
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - L Peruzzo
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - P Petrov
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - Y Petrov
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - F Petrucci
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - R Piandani
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M Piccini
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - J Pinzino
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - I Polenkevich
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - L Pontisso
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - Yu Potrebenikov
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | | | - M Raggi
- Dipartimento di Fisica, Sapienza Università di Roma e INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - A Romano
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - P Rubin
- George Mason University, Fairfax, Virginia 22030, USA
| | - G Ruggiero
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - V Ryjov
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - A Salamon
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - C Santoni
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - G Saracino
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - F Sargeni
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - S Schuchmann
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - V Semenov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - A Sergi
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - A Shaikhiev
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - S Shkarovskiy
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - D Soldi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - M Sozzi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - T Spadaro
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - F Spinella
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - A Sturgess
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - V Sugonyaev
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - J Swallow
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - S Trilov
- University of Bristol, Bristol BS8 1TH, United Kingdom
| | - P Valente
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - B Velghe
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - S Venditti
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - P Vicini
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - R Volpe
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - M Vormstein
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - H Wahl
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - R Wanke
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - B Wrona
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - O Yushchenko
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - M Zamkovsky
- Charles University, 116 36 Prague 1, Czech Republic
| | - A Zinchenko
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| |
Collapse
|
20
|
Pyromali I, Perani A, Nizou A, Benslimane N, Derouault P, Bourthoumieu S, Fradin M, Sole G, Duval F, Gomes C, Favreau F, Sturtz F, Magdelaine C, Lia AS. New structural variations responsible for Charcot-Marie-Tooth disease: The first two large KIF5A deletions detected by CovCopCan software. Comput Struct Biotechnol J 2021; 19:4265-4272. [PMID: 34429846 PMCID: PMC8355829 DOI: 10.1016/j.csbj.2021.07.037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 07/19/2021] [Accepted: 07/28/2021] [Indexed: 02/01/2023] Open
Abstract
Next-generation sequencing (NGS) allows the detection of mutations in inherited genetic diseases, like the Charcot-Marie-Tooth disease (CMT) which is the most common hereditary peripheral neuropathy. The majority of mutations detected by NGS are single nucleotide variants (SNVs) or small indels, while structural variants (SVs) are often underdiagnosed. PMP22 was the first gene described as being involved in CMT via a SV of duplication type. To date, more than 90 genes are known to be involved in CMT, with mainly SNVs and short indels described. Herein targeted NGS and the CovCopCan bioinformatic tool were used in two unrelated families, both presenting with typical CMT symptoms with pyramidal involvement. We have discovered two large SVs in KIF5A, a gene known to cause axonal forms of CMT (CMT2) in which no SVs have yet been described. In the first family, the patient presented with a large deletion of 12 kb in KIF5A from Chr12:57,956,278 to Chr12:57,968,335 including exons 2–15, that could lead to mutation c.(130-943_c.1717-533del), p.(Gly44_Leu572del). In the second family, two cases presented with a large deletion of 3 kb in KIF5A from Chr12:57,974,133 to Chr12:57,977,210 including exons 24–28, that could lead to mutation c.(2539-605_*36 + 211del), p.(Leu847_Ser1032delins33). In addition, bioinformatic sequence analysis revealed that a NAHR (Non-Allelic-Homologous-Recombination) mechanism, such as those in the PMP22 duplication, could be responsible for one of the KIF5A SVs and could potentially be present in a number of other patients. This study reveals that large KIF5A deletions can cause CMT2 and highlights the importance of analyzing not only the SNVs but also the SVs during diagnosis of neuropathies.
Collapse
Key Words
- ALS, Amyotrophic Lateral Sclerosis
- CMT, Charcot-Marie-Tooth
- CMT2, Charcot-Marie-Tooth type 2
- CNV, Copy Number Variants
- Charcot-Marie-Tooth
- CovCopCan
- DSMA, Distal-Spinal-Muscular-Atrophy
- HSP10, Hereditary-Spastic-Paraplegia-type-10
- KIF5A
- NAHR, Non-Allelic Homologous Recombination
- NEIMY, Neonatal-Intractable-MYoclonus
- NGS
- NGS, Next Generation Sequencing
- SNV, Single Nucleotide Variant
- SV, Structural Variant
- Structural variations
Collapse
Affiliation(s)
| | - Alexandre Perani
- CHU Limoges, Service de Biochimie et de Génétique Moléculaire, F-87000 Limoges, France
| | | | | | - Paco Derouault
- CHU Limoges, Service de Bioinformatique, F-87000 Limoges, France
| | - Sylvie Bourthoumieu
- CHU Limoges, Service de Cytogénétique, Génétique Médicale et Biologie de la Reproduction, F-87000 Limoges, France
| | - Mélanie Fradin
- CHU Rennes, CLAD Ouest, Service de Génétique, F-35203 Rennes, France
| | - Guilhem Sole
- CHU Bordeaux (Groupe Hospitalier Pellegrin), Service de Neurologie et Centre de Référence des Maladies Neuromusculaires AOC, F-33000 Bordeaux, France
| | - Fanny Duval
- CHU Bordeaux (Groupe Hospitalier Pellegrin), Service de Neurologie et Centre de Référence des Maladies Neuromusculaires AOC, F-33000 Bordeaux, France
| | - Constantin Gomes
- Hôpital Pontchaillou, Département de Neurophysiologie, F-35200 Rennes, France
| | - Frédéric Favreau
- Univ. Limoges, MMNP, EA6309, F-87000 Limoges, France.,CHU Limoges, Service de Biochimie et de Génétique Moléculaire, F-87000 Limoges, France
| | - Franck Sturtz
- Univ. Limoges, MMNP, EA6309, F-87000 Limoges, France.,CHU Limoges, Service de Biochimie et de Génétique Moléculaire, F-87000 Limoges, France
| | - Corinne Magdelaine
- Univ. Limoges, MMNP, EA6309, F-87000 Limoges, France.,CHU Limoges, Service de Biochimie et de Génétique Moléculaire, F-87000 Limoges, France
| | - Anne-Sophie Lia
- Univ. Limoges, MMNP, EA6309, F-87000 Limoges, France.,CHU Limoges, Service de Biochimie et de Génétique Moléculaire, F-87000 Limoges, France.,CHU Limoges, Service de Bioinformatique, F-87000 Limoges, France
| |
Collapse
|
21
|
Duplaine A, Prot C, Le-Masson G, Soulages A, Duval F, Dutriaux C, Prey S. Myasthenia Gravis Lambert-Eaton overlap syndrome induced by nivolumab in a metastatic melanoma patient. Neurol Sci 2021; 42:5377-5378. [PMID: 34427792 DOI: 10.1007/s10072-021-05557-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Accepted: 07/31/2021] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Myasthenia gravis (MG) Lambert-Eaton (LE) overlap syndrome is a rare condition. Here, we describe the first case of MG-LE overlap syndrome revealed by the anti-programmed cell death 1 inhibitor, nivolumab, in a patient treated for metastatic melanoma. CASE Three months after receiving nivolumab and 1 month after brain metastasis radiotherapy, our patient developed generalized fatigue with intermittent ptosis and swallowing difficulty suggesting a myasthenic syndrome. Electromyogram findings, anti-acetylcholine receptor, and anti-calcium channel antibodies levels were consistent with an immune-related myasthenic syndrome with specific features for both MG and LE syndromes. Immunotherapy with nivolumab was stopped. Patient was treated with systemic immunosuppressive and anti-cholinesterase drugs, with remarkable improvement of his neurological symptoms. Prolonged partial remission was obtained for his metastatic melanoma without need for a third-line treatment. Two years later, a relapse of hismyasthenic symptoms was observed along with new neurological symptoms related to brain radiation necrosis. CONCLUSION We describe the first case of MG-LE overlap syndrome diagnosed after anti-PD1 immunotherapy for metastatic melanoma, which appeared after radiation therapy and then relapsed after brain radiation necrosis. We hypothesized a role for brain inflammation as a trigger for MG-LE onset. Neuro-muscular junctions disease induced or revealed by checkpoint inhibitors can be challenging and requires long-term follow-up.
Collapse
Affiliation(s)
- Alexandra Duplaine
- Service de Dermatologie, CHU de Bordeaux, Groupe Hospitalier Saint André, 1, rue Jean Burguet, 33000, Bordeaux, France
| | - Camille Prot
- Service de Dermatologie, CHU de Bordeaux, Groupe Hospitalier Saint André, 1, rue Jean Burguet, 33000, Bordeaux, France
| | | | | | - Fanny Duval
- Service de Neurologie, CHU de Bordeaux, 33000, Bordeaux, France
| | - Caroline Dutriaux
- Service de Dermatologie, CHU de Bordeaux, Groupe Hospitalier Saint André, 1, rue Jean Burguet, 33000, Bordeaux, France.,University of Bordeaux, Inserm U-1035, 33000, Bordeaux, France
| | - Sorilla Prey
- Service de Dermatologie, CHU de Bordeaux, Groupe Hospitalier Saint André, 1, rue Jean Burguet, 33000, Bordeaux, France. .,University of Bordeaux, Inserm U-1035, 33000, Bordeaux, France.
| |
Collapse
|
22
|
Mathis S, Le Masson G, Soulages A, Duval F, Carla L, Vallat JM, Solé G. Olfaction and anosmia: From ancient times to COVID-19. J Neurol Sci 2021; 425:117433. [PMID: 33848701 DOI: 10.1016/j.jns.2021.117433] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 03/30/2021] [Accepted: 03/31/2021] [Indexed: 12/30/2022]
Abstract
Olfaction, one of our five main qualitative sensory abilities, is the action of smelling or the capacity to smell. Olfactory impairment can be a sign of a medical problem, from a benign nasal/sinus problem up to a potentially serious brain injury. However, although clinicians (neurologists or not) usually test the olfactory nerves in specific clinical situations (for example, when a neurodegenerative disorder is suspected), they may omit such tests in many other situations. With the recent COVID-19 pandemic, the resurgence of anosmia has reminded us of the importance of testing this sensorineural function. We retrace here the main historical steps and discoveries concerning olfaction and anosmia.
Collapse
Affiliation(s)
- Stéphane Mathis
- Department of Neurology (Nerve-Muscle Unit), University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, 1 place Amélie Raba-Léon, 33076 Bordeaux, France; Grand Sud-Ouest' National Reference Center for neuromuscular disorders, University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, 1 place Amélie Raba-Léon, 33076 Bordeaux, France; ALS Center, University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, 1 place Amélie Raba-Léon, 33076 Bordeaux, France.
| | - Gwendal Le Masson
- Department of Neurology (Nerve-Muscle Unit), University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, 1 place Amélie Raba-Léon, 33076 Bordeaux, France; Grand Sud-Ouest' National Reference Center for neuromuscular disorders, University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, 1 place Amélie Raba-Léon, 33076 Bordeaux, France; ALS Center, University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, 1 place Amélie Raba-Léon, 33076 Bordeaux, France; Neurocentre François Magendie, Unité INSERM 1215, 146 Rue Léo Saignat, 33077 Bordeaux Cedex, France
| | - Antoine Soulages
- Department of Neurology (Nerve-Muscle Unit), University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, 1 place Amélie Raba-Léon, 33076 Bordeaux, France; Grand Sud-Ouest' National Reference Center for neuromuscular disorders, University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, 1 place Amélie Raba-Léon, 33076 Bordeaux, France; ALS Center, University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, 1 place Amélie Raba-Léon, 33076 Bordeaux, France
| | - Fanny Duval
- Department of Neurology (Nerve-Muscle Unit), University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, 1 place Amélie Raba-Léon, 33076 Bordeaux, France; Grand Sud-Ouest' National Reference Center for neuromuscular disorders, University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, 1 place Amélie Raba-Léon, 33076 Bordeaux, France
| | - Louis Carla
- Department of Neurology (Nerve-Muscle Unit), University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, 1 place Amélie Raba-Léon, 33076 Bordeaux, France
| | - Jean-Michel Vallat
- Department and Laboratory of Neurology, National Reference Center for 'Rare Peripheral Neuropathies', University Hospital of Limoges (CHU Limoges), Dupuytren Hospital, 2 avenue Martin Luther King, 87042 Limoges, France
| | - Guilhem Solé
- Department of Neurology (Nerve-Muscle Unit), University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, 1 place Amélie Raba-Léon, 33076 Bordeaux, France; Grand Sud-Ouest' National Reference Center for neuromuscular disorders, University Hospital of Bordeaux (CHU Bordeaux), Pellegrin Hospital, 1 place Amélie Raba-Léon, 33076 Bordeaux, France
| |
Collapse
|
23
|
Solé G, Mathis S, Friedman D, Salort-Campana E, Tard C, Bouhour F, Magot A, Annane D, Clair B, Le Masson G, Soulages A, Duval F, Carla L, Violleau MH, Saulnier T, Segovia-Kueny S, Kern L, Antoine JC, Beaudonnet G, Audic F, Kremer L, Chanson JB, Nadaj-Pakleza A, Stojkovic T, Cintas P, Spinazzi M, Foubert-Samier A, Attarian S. Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis. Neurology 2021; 96:e2109-e2120. [PMID: 33568541 DOI: 10.1212/wnl.0000000000011669] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Accepted: 01/22/2021] [Indexed: 12/18/2022] Open
Abstract
OBJECTIVE To describe the clinical characteristics and outcomes of coronavirus disease 2019 (COVID-19) among patients with myasthenia gravis (MG) and identify factors associated with COVID-19 severity in patients with MG. METHODS The CO-MY-COVID registry was a multicenter, retrospective, observational cohort study conducted in neuromuscular referral centers and general hospitals of the FILNEMUS (Filière Neuromusculaire) network (between March 1, 2020, and June 8, 2020), including patients with MG with a confirmed or highly suspected diagnosis of COVID-19. COVID-19 was diagnosed based on a PCR test from a nasopharyngeal swab or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology, thoracic CT scan, or typical symptoms. The main outcome was COVID-19 severity based on location of treatment/management (home, hospitalized in a medical unit, or in an intensive care unit). We collected information on demographic variables, general history, and risk factors for severe COVID-19. Multivariate ordinal regression models were used to identify factors associated with severe COVID-19 outcomes. RESULTS Among 3,558 patients with MG registered in the French database for rare disorders, 34 (0.96%) had COVID-19. The mean age at COVID-19 onset was 55.0 ± 19.9 years (mean MG duration: 8.5 ± 8.5 years). By the end of the study period, 28 patients recovered from COVID-19, 1 remained affected, and 5 died. Only high Myasthenia Gravis Foundation of America (MGFA) class (≥IV) before COVID-19 was associated with severe COVID-19 (p = 0.004); factors that were not associated included sex, MG duration, and medium MGFA classes (≤IIIb). The type of MG treatment had no independent effect on COVID-19 severity. CONCLUSIONS This registry-based cohort study shows that COVID-19 had a limited effect on most patients, and immunosuppressive medications and corticosteroids used for MG management are not risk factors for poorer outcomes. However, the risk of severe COVID-19 is elevated in patients with high MGFA classes (odds ratio, 102.6 [4.4-2,371.9]). These results are important for establishing evidence-based guidelines for the management of patients with MG during the COVID-19 pandemic.
Collapse
Affiliation(s)
- Guilhem Solé
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France.
| | - Stéphane Mathis
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Diane Friedman
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Emmanuelle Salort-Campana
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Céline Tard
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Françoise Bouhour
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Armelle Magot
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Djillali Annane
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Bernard Clair
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Gwendal Le Masson
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Antoine Soulages
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Fanny Duval
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Louis Carla
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Marie-Hélène Violleau
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Tiphaine Saulnier
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Sandrine Segovia-Kueny
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Léa Kern
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Jean-Christophe Antoine
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Guillemette Beaudonnet
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Frédérique Audic
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Laurent Kremer
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Jean-Baptiste Chanson
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Aleksandra Nadaj-Pakleza
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Tanya Stojkovic
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Pascal Cintas
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Marco Spinazzi
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Alexandra Foubert-Samier
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| | - Shahram Attarian
- From the Referral Center for Neuromuscular Diseases AOC (G.S., S.M., G.L.M., A.S., F.D., L.C., M.-H.V.) and ALS Center (S.M., G.L.M., A.S., L.C.), Nerve-Muscle Unit, University Hospitals of Bordeaux (Pellegrin Hospital), University of Bordeaux; Department of Intensive Care (D.F., D.A., B.C.), Raymond Poincare University Hospital, Garches; Referral Center for Neuromuscular Diseases and ALS (E.S.-C., S.A.) and Referral Center for Neuromuscular Diseases, Neuropediatric Unit (F.A.), Timone University Hospital, Aix-Marseille University, Marseille; Department of Neurology, Referral Center for Neuromuscular Diseases (C.T.), University Hospitals of Lille; ENMG Unit, Referral Center for Neuromuscular Diseases (F.B.), University Hospitals of Lyon (Neurologic Hospital Pierre Wertheimer); Referral Center for Neuromuscular Diseases (A.M.), University Hospitals of Nantes; Inserm, UMR1219 (T.S., A.F.-S.), Bordeaux Population Health Research Center, ISPED, University of Bordeaux; Neurodegenerative Diseases Institute, French Reference Centre for MSA (T.S., A.F.-S.), University Hospitals of Bordeaux; AFM-Téléthon (S.S.-K.), Evry; Department of Neurology (L.K.), General Hospital of Le Mans; Department of Neurology (J.-C.A.), University Hospital of Saint-Etienne; Clinical Neurophysiology and Epileptology Department (G.B.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Neurology Department (L.K., J.-B.C., A.N.-P.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," University Hospitals of Strasbourg; APHP (Pitié-Salpêtrière Hospital) (T.S.), Referral Center for Neuromuscular Diseases "Nord-Est-Ile de France," Sorbonne University, Paris; Referral Center for Neuromuscular Diseases, Department of Neurology (P.C.), University Hospitals of Toulouse (Purpan Hospital); and Referral Center for Neuromuscular Diseases, Department of Neurology (M.S.), University Hospital of Angers, France
| |
Collapse
|
24
|
Montes G, Duval F, Eldani C, Amico S, Gerard E, Dutriaux C, Herran C, Poullenot F, Sole G, Guerin C, Zerbib F, Celerier P, Prey S. Vomissements incoercibles révélant une achalasie de l’œsophage avec AC anti-GAD65+ : une complication neurologique dysautonomique méconnue de l’association ipilimumab+nivolumab. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
25
|
Mathis S, Duval F, Soulages A, Solé G, Le Masson G. The ataxic neuropathies. J Neurol 2020; 268:3675-3689. [DOI: 10.1007/s00415-020-09994-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Revised: 06/09/2020] [Accepted: 06/10/2020] [Indexed: 12/15/2022]
|
26
|
Garcia FD, Duval F, Lopera FG, Mokrani MC, Hode Y, Fattah S, Diep TS. Weight Gain and Hyperprolactinemia in Schizophrenic Patients Treated During Twelve Months with Long Acting Risperidone. Eur Psychiatry 2020. [DOI: 10.1016/s0924-9338(09)71237-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Background:Risperidone (RISP) may induce both elevated prolactin (PRL) levels and weight gain. the aim of this study was to evaluate body weight and mass index (BMI), and PRL modifications in schizophrenic patients treated for 1 year with long-acting risperidone (LAR).Methods:Body weight and BMI (calculated as weight in kilograms divide by height in meter squared) were determined at baseline and at endpoint in 19 schizophrenic patients (9 men and 10 women; mean[SEM] age 33.4[2.9] years). PRL levels were determined at baseline, after oral risperidone treatment (mean length of treatment: 79[30] days; mean dose: 5.8[0.5] mg daily) and during a 12 month treatment with LAR (mean dose: 50[10] mg every 2 weeks; PRL levels were measured before each injection).Results:At endpoint, a significant weight gain (Δweight: 8,1[1,4] kg) and BMI (ΔBMI: 2,9[0,5] kg/m²) was observed (both p< 0.0002). Compared with baseline, PRL levels were significantly increased (p< 0.0007; mean ΔPRL: 33[8] ng/ml). There was an association between ΔBMI>1,5 kg/m² and ΔPRL>40 ng/ ml (p< 0.04). Moreover ΔBMI was linked to the length of treatment (rho=0.47; n=19; p< 0.05).Conclusions:Our results suggest a link between weight gain and long term hyperprolactinemia in patients treated with LAR. It has been hypothesized that PRL may have a role in the regulation of food intake by increasing leptin synthesis and secretion.
Collapse
|
27
|
Manson G, Maria ATJ, Poizeau F, Danlos FX, Kostine M, Brosseau S, Aspeslagh S, Du Rusquec P, Roger M, Pallix-Guyot M, Ruivard M, Dousset L, Grignou L, Psimaras D, Pluvy J, Quéré G, Grados F, Duval F, Bourdain F, Maigne G, Perrin J, Godbert B, Taifas BI, Forestier A, Voisin AL, Martin-Romano P, Baldini C, Marabelle A, Massard C, Honnorat J, Lambotte O, Michot JM. Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. J Immunother Cancer 2019; 7:337. [PMID: 31796119 PMCID: PMC6892018 DOI: 10.1186/s40425-019-0821-8] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Accepted: 11/13/2019] [Indexed: 02/07/2023] Open
Abstract
Background Paraneoplastic syndromes (PNS) are autoimmune disorders specifically associated with cancer. There are few data on anti-PD-1 or anti-PD-L1 immunotherapy in patients with a PNS. Our objective was to describe the outcome for patients with a pre-existing or newly diagnosed PNS following the initiation of anti-PD-1 or anti-PD-L1 immunotherapy. Methods We included all adult patients (aged ≥18) treated with anti-PD-1 or anti-PD-L1 immunotherapy for a solid tumor, diagnosed with a PNS, and registered in French pharmacovigilance databases. Patients were allocated to cohorts 1 and 2 if the PNS had been diagnosed before vs. after the initiation of immunotherapy, respectively. Findings Of the 1304 adult patients screened between June 27th, 2014, and January 2nd, 2019, 32 (2.45%) had a PNS and were allocated to either cohort 1 (n = 16) or cohort 2 (n = 16). The median (range) age was 64 (45–88). The tumor types were non-small-cell lung cancer (n = 15, 47%), melanoma (n = 6, 19%), renal carcinoma (n = 3, 9%), and other malignancies (n = 8, 25%). Eleven (34%) patients presented with a neurologic PNS, nine (28%) had a rheumatologic PNS, eight (25%) had a connective tissue PNS, and four (13%) had other types of PNS. The highest severity grade for the PNS was 1–2 in 10 patients (31%) and ≥ 3 in 22 patients (69%). Four patients (13%) died as a result of the progression of a neurologic PNS (encephalitis in three cases, and Lambert-Eaton syndrome in one case). Following the initiation of immunotherapy, the PNS symptoms worsened in eight (50%) of the 16 patients in cohort 1. Interpretation Our results show that PNSs tend to be worsened or revealed by anti-PD-1 or anti-PD-L1 immunotherapy. Cases of paraneoplastic encephalitis are of notable concern, in view of their severity. When initiating immunotherapy, physicians should carefully monitor patients with a pre-existing PNS.
Collapse
Affiliation(s)
- Guillaume Manson
- Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.,Department of Hematology, University Hospital of Rennes, Rennes, France
| | - Alexandre Thibault Jacques Maria
- Department of Internal Medicine and Multiorgan Diseases, Referral Center for Auto-immune Diseases, Saint-Eloi Hospital Montpellier University, Montpellier, France
| | - Florence Poizeau
- Department of Dermatology, Rennes University Hospital, Rennes, France
| | - François-Xavier Danlos
- Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Marie Kostine
- Rheumatology Department, Bordeaux University Hospital, Bordeaux, France
| | - Solenn Brosseau
- AP-HP, Hôpital Bichat-Claude Bernard, Centre Investigation Clinique 1425, Thoracic Oncology Department, University Paris-Diderot, Paris, France
| | - Sandrine Aspeslagh
- Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium
| | - Pauline Du Rusquec
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, France
| | - Maxime Roger
- Department of Pulmonology and Thoracic Oncology, Rouen University Hospital, Rouen, France
| | | | - Marc Ruivard
- Internal Medicine Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - Léa Dousset
- Dermatology Department, Bordeaux University Hospital, Bordeaux, France
| | | | - Dimitri Psimaras
- AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin et Université Pierre et Marie Curie-Paris 6, Centre de Compétence des Syndromes Neurologiques Paranéoplasiques et Encéphalites Auto-immunes, Paris, France
| | - Johan Pluvy
- AP-HP, Hôpital Bichat-Claude Bernard, Centre Investigation Clinique 1425, Thoracic Oncology Department, University Paris-Diderot, Paris, France
| | - Gilles Quéré
- Oncology Departement, Brest Hôpital Morvan Centre Hospitalier Régional Universitaire, Brest, France
| | - Franck Grados
- Amiens University Hospital, Rheumatology Department, University of Picardie - Jules Verne, Amiens, France
| | - Fanny Duval
- Neurology Department, Bordeaux University Hospital, Bordeaux, France
| | - Frederic Bourdain
- Departement de Neurologie, Centre Hospitalier de la Côte Basque, Bayonne, France
| | - Gwenola Maigne
- Department of Internal Medicine, Caen University Hospital, Caen, France
| | - Julie Perrin
- Pneumology Department, Metz Robert Schuman Hospital, Metz, France
| | - Benoit Godbert
- Pneumology Department, Metz Robert Schuman Hospital, Metz, France
| | | | | | - Anne-Laure Voisin
- Gustave Roussy, Université Paris-Saclay, Unité fonctionnelle de Pharmacovigilance, F-94805, Villejuif, France
| | - Patricia Martin-Romano
- Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Capucine Baldini
- Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Aurélien Marabelle
- Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Christophe Massard
- Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
| | - Jérôme Honnorat
- Hospices Civils de Lyon, French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, SynatAc Team, Institut NeuroMyoGène. INSERM U1217/CNRS UMR 5310, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France
| | - Olivier Lambotte
- AP-HP, Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, Le Kremlin-Bicêtre, France.,Université Paris Sud, Centre de Recherche en Immunologie des Infections Virales et des Maladies Auto-Immunes, INSERM U1184, Le Kremlin-Bicêtre, France.,Division d'Immunovirologie, Commissariat à l'Energie Atomique et aux Energies Alternatives, Fontenay-aux- Roses, France
| | - Jean-Marie Michot
- Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
| |
Collapse
|
28
|
Tang MAH, Mathis S, Duffau P, Cazenave P, Solé G, Duval F, Soulages A, Le Masson G. Prognostic factor of poor outcome in anti-MAG neuropathy: clinical and electrophysiological analysis of a French Cohort. J Neurol 2019; 267:561-571. [PMID: 31705291 DOI: 10.1007/s00415-019-09618-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Revised: 11/01/2019] [Accepted: 11/02/2019] [Indexed: 12/12/2022]
Abstract
BACKGROUND Anti-MAG polyneuropathy (anti-MAG PN) is an immune-mediated peripheral sensorimotor neuropathy characterized by distal demyelination and ataxia. However, this disorder, unlike other immune-mediated neuropathies, is difficult to treat in most cases. METHOD We retrospectively collected all anti-MAG PN patients followed in two hospitals for a period of 12 years to determine prognostic factors, especially those that indicated a good response to the various therapeutic strategies used. RESULTS Forty-seven patients were included in the study; of these, 61% had a classical 'distal demyelinating pattern', 34.2% had a 'CIDP-like pattern', and the others had an 'axonal pattern'. The most commonly used treatments were intravenous immunoglobulin (IVIg) as the first-line treatment and rituximab as the second- or third-line treatment. No prognostic factor was identified for IVIg, but electrophysiological parameters at onset were better in patients with a good response to rituximab than in non-responder patients, even though mild or high disability was observed in nearly half the patients at last examination. CONCLUSION Even though disability seems to progress in most cases despite the treatments used, our results suggest that an early electrophysiological reduction in sensory nerves could be considered a 'red flag' for the prompt initiation of rituximab to try to delay long-term disability.
Collapse
Affiliation(s)
- Marie-Ange Hoang Tang
- Department of Neurology, Nerve-Muscle Unit, CHU Bordeaux (Groupe Hospitalier Pellegrin), University of Bordeaux, Place Amélie Raba-Léon, 33000, Bordeaux, France
| | - Stéphane Mathis
- Department of Neurology, Nerve-Muscle Unit, CHU Bordeaux (Groupe Hospitalier Pellegrin), University of Bordeaux, Place Amélie Raba-Léon, 33000, Bordeaux, France.,Centre de Référence des Pathologies Neuromusculaires, CHU Bordeaux (Groupe Hospitalier Pellegrin), University of Bordeaux, Place Amélie Raba-Léon, 33000, Bordeaux, France
| | - Pierre Duffau
- Department of Internal Medicine and Clinical Immunology, CHU Bordeaux (Groupe Hospitalier Saint-André), University of Bordeaux, Place Amélie Raba-Léon, 33000, Bordeaux, France
| | - Philippe Cazenave
- Department of Neurology, Robert Boulin Hospital, 112 rue de la Marne, 33505, Libourne, France
| | - Guilhem Solé
- Department of Neurology, Nerve-Muscle Unit, CHU Bordeaux (Groupe Hospitalier Pellegrin), University of Bordeaux, Place Amélie Raba-Léon, 33000, Bordeaux, France.,Centre de Référence des Pathologies Neuromusculaires, CHU Bordeaux (Groupe Hospitalier Pellegrin), University of Bordeaux, Place Amélie Raba-Léon, 33000, Bordeaux, France
| | - Fanny Duval
- Department of Neurology, Nerve-Muscle Unit, CHU Bordeaux (Groupe Hospitalier Pellegrin), University of Bordeaux, Place Amélie Raba-Léon, 33000, Bordeaux, France.,Centre de Référence des Pathologies Neuromusculaires, CHU Bordeaux (Groupe Hospitalier Pellegrin), University of Bordeaux, Place Amélie Raba-Léon, 33000, Bordeaux, France
| | - Antoine Soulages
- Department of Neurology, Nerve-Muscle Unit, CHU Bordeaux (Groupe Hospitalier Pellegrin), University of Bordeaux, Place Amélie Raba-Léon, 33000, Bordeaux, France
| | - Gwendal Le Masson
- Department of Neurology, Nerve-Muscle Unit, CHU Bordeaux (Groupe Hospitalier Pellegrin), University of Bordeaux, Place Amélie Raba-Léon, 33000, Bordeaux, France. .,Centre de Référence des Pathologies Neuromusculaires, CHU Bordeaux (Groupe Hospitalier Pellegrin), University of Bordeaux, Place Amélie Raba-Léon, 33000, Bordeaux, France.
| |
Collapse
|
29
|
Ben Yaou R, Stojkovic T, Cerino M, Duval F, Juntas-Morales R, Nelson I, Beuvin M, Lacene E, Sternberg D, Nectoux J, Martin-Negrier M, Bartoli M, Cossee M, Leturcq F, Sole G, Krahn M, Romero N, Eymard B, Bonne G. P.252LGMD, exercise intolerance, ptosis, ophthalmoplegia and dermatologic features: the phenotypic pleiotropy of plectinopathies in 8 French families. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Mandia D, Chaussenot A, Besson G, Lamari F, Castelnovo G, Curot J, Duval F, Giral P, Lecerf JM, Roland D, Pierdet H, Douillard C, Nadjar Y. Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults. J Neurol 2019. [PMID: 31115677 DOI: 10.1007/s00415‐019‐09377‐y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Cerebrotendineous xanthomatosis (CTX) is an autosomal recessive disorder of bile acids synthesis. Patients may present with a variety of clinical manifestations: bilateral cataract and chronic diarrhea during childhood, then occurrence of neurological debilitating symptoms in adulthood (cognitive decline, motor disorders). Plasma cholestanol is used as a diagnostic marker of CTX, and to monitor the response to the treatment. Current treatment for CTX is chenodeoxycholic acid (CDCA), which was reported to improve and/or stabilize clinical status and decrease levels of plasma cholestanol. Rare published reports have also suggested a potential efficacy of cholic acid (CA) in patients with CTX. In this retrospective Franco-Belgian multicentric study, we collected data from 12 patients treated with CA, evaluating their clinical status, cholestanol levels and adverse effects during the treatment period. The population was divided in two subgroups: treatment-naive (who never had CDCA prior to CA) and non-treatment-naive patients (who had CDCA prior to CA introduction). We found that treatment with CA significantly and strongly reduced cholestanol levels in all patients. Additionally, 10 out of 12 patients clinically improved or stabilized with CA treatment. Worsening was noted in one treatment-naïve patient and one non-treatment-naïve patient, but both patients experienced similar outcomes with CDCA treatment as well. No adverse effects were reported from patients with CA treatment, whereas elevated transaminases were observed in some patients while they were treated with CDCA. In conclusion, these findings suggest that CA may be a suitable alternative treatment for CTX, especially in patients with side effects related to CDCA.
Collapse
Affiliation(s)
- Daniele Mandia
- Neurology Department, Reference Center for Lysosomal Diseases, Neurogenetics and Metabolism Unit, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France
| | - Annabelle Chaussenot
- Service de Génétique Médicale, Centre de Référence des Maladies Mitochondriales, Hôpital de l'Archet 2, 151 Route de Saint-Antoine de Ginestière, B.P.3079, 06202, Nice Cedex 3, France
| | - Gérard Besson
- Unité Neurologie générale, Pôle Psychiatrie, Neurologie et Rééducation Neurologique, Service de Neurologie, CHU de Grenoble site Nord-Hôpital Albert Michallon, boulevard de la Chantourne, CS10217, 38043, Grenoble Cedex 9, France
| | - Foudil Lamari
- UF Biochimie des maladies neurométaboliques-Département de Biochimie métabolique, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France
| | - Giovanni Castelnovo
- Neurological Department, Centre hospitalo-universitaire Caremeau, place du Professeur Debré, 30029, Nîmes Cedex, France
| | - Jonathan Curot
- Department of Neurology, Toulouse University Hospital, 31059, Toulouse, France.,Centre de Recherche Cerveau et Cognition, CNRS, UMR5549, 31052, Toulouse, France
| | - Fanny Duval
- Department of Neurology (Nerve-Muscle Unit), CHU Bordeaux (Pellegrin Hospital), 33076, Bordeaux, France
| | - Philippe Giral
- Inserm, Institute of Cardiometabolism and Nutrition (ICAN), UMR_S1166, Sorbonne Université, Paris, France.,Department of Endocrinology-Metabolism, AP-HP, Hôpital de la Pitié, Paris, France
| | - Jean-Michel Lecerf
- Service de Nutrition & Activité Physique, Institut Pasteur de Lille, 1, rue du professeur Calmette, 59019, Lille, France.,Service de Médecine Interne, Hôpital Claude Huriez-CHRU de Lille, 59037, Lille, France
| | - Dominique Roland
- Institut de Pathologie et de Génétique ASBL, Centre Agréé des Maladies Héréditaires du Métabolisme, Centre de Génétique Humaine, Avenue Georges Lemaitre, 25, 6041, Gosselies, Belgium
| | - Heloise Pierdet
- Neurology Department, Reference Center for Lysosomal Diseases, Neurogenetics and Metabolism Unit, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France
| | - Claire Douillard
- Endocrinology and Metabolism Department, Lille University Hospital, C. Huriez Hospital, 1, rue Polonovski, 59037, Lille Cedex, France
| | - Yann Nadjar
- Neurology Department, Reference Center for Lysosomal Diseases, Neurogenetics and Metabolism Unit, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
| |
Collapse
|
31
|
Mandia D, Chaussenot A, Besson G, Lamari F, Castelnovo G, Curot J, Duval F, Giral P, Lecerf JM, Roland D, Pierdet H, Douillard C, Nadjar Y. Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults. J Neurol 2019; 266:2043-2050. [PMID: 31115677 DOI: 10.1007/s00415-019-09377-y] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Revised: 04/29/2019] [Accepted: 05/15/2019] [Indexed: 02/02/2023]
Abstract
Cerebrotendineous xanthomatosis (CTX) is an autosomal recessive disorder of bile acids synthesis. Patients may present with a variety of clinical manifestations: bilateral cataract and chronic diarrhea during childhood, then occurrence of neurological debilitating symptoms in adulthood (cognitive decline, motor disorders). Plasma cholestanol is used as a diagnostic marker of CTX, and to monitor the response to the treatment. Current treatment for CTX is chenodeoxycholic acid (CDCA), which was reported to improve and/or stabilize clinical status and decrease levels of plasma cholestanol. Rare published reports have also suggested a potential efficacy of cholic acid (CA) in patients with CTX. In this retrospective Franco-Belgian multicentric study, we collected data from 12 patients treated with CA, evaluating their clinical status, cholestanol levels and adverse effects during the treatment period. The population was divided in two subgroups: treatment-naive (who never had CDCA prior to CA) and non-treatment-naive patients (who had CDCA prior to CA introduction). We found that treatment with CA significantly and strongly reduced cholestanol levels in all patients. Additionally, 10 out of 12 patients clinically improved or stabilized with CA treatment. Worsening was noted in one treatment-naïve patient and one non-treatment-naïve patient, but both patients experienced similar outcomes with CDCA treatment as well. No adverse effects were reported from patients with CA treatment, whereas elevated transaminases were observed in some patients while they were treated with CDCA. In conclusion, these findings suggest that CA may be a suitable alternative treatment for CTX, especially in patients with side effects related to CDCA.
Collapse
Affiliation(s)
- Daniele Mandia
- Neurology Department, Reference Center for Lysosomal Diseases, Neurogenetics and Metabolism Unit, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France
| | - Annabelle Chaussenot
- Service de Génétique Médicale, Centre de Référence des Maladies Mitochondriales, Hôpital de l'Archet 2, 151 Route de Saint-Antoine de Ginestière, B.P.3079, 06202, Nice Cedex 3, France
| | - Gérard Besson
- Unité Neurologie générale, Pôle Psychiatrie, Neurologie et Rééducation Neurologique, Service de Neurologie, CHU de Grenoble site Nord-Hôpital Albert Michallon, boulevard de la Chantourne, CS10217, 38043, Grenoble Cedex 9, France
| | - Foudil Lamari
- UF Biochimie des maladies neurométaboliques-Département de Biochimie métabolique, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France
| | - Giovanni Castelnovo
- Neurological Department, Centre hospitalo-universitaire Caremeau, place du Professeur Debré, 30029, Nîmes Cedex, France
| | - Jonathan Curot
- Department of Neurology, Toulouse University Hospital, 31059, Toulouse, France
- Centre de Recherche Cerveau et Cognition, CNRS, UMR5549, 31052, Toulouse, France
| | - Fanny Duval
- Department of Neurology (Nerve-Muscle Unit), CHU Bordeaux (Pellegrin Hospital), 33076, Bordeaux, France
| | - Philippe Giral
- Inserm, Institute of Cardiometabolism and Nutrition (ICAN), UMR_S1166, Sorbonne Université, Paris, France
- Department of Endocrinology-Metabolism, AP-HP, Hôpital de la Pitié, Paris, France
| | - Jean-Michel Lecerf
- Service de Nutrition & Activité Physique, Institut Pasteur de Lille, 1, rue du professeur Calmette, 59019, Lille, France
- Service de Médecine Interne, Hôpital Claude Huriez-CHRU de Lille, 59037, Lille, France
| | - Dominique Roland
- Institut de Pathologie et de Génétique ASBL, Centre Agréé des Maladies Héréditaires du Métabolisme, Centre de Génétique Humaine, Avenue Georges Lemaitre, 25, 6041, Gosselies, Belgium
| | - Heloise Pierdet
- Neurology Department, Reference Center for Lysosomal Diseases, Neurogenetics and Metabolism Unit, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France
| | - Claire Douillard
- Endocrinology and Metabolism Department, Lille University Hospital, C. Huriez Hospital, 1, rue Polonovski, 59037, Lille Cedex, France
| | - Yann Nadjar
- Neurology Department, Reference Center for Lysosomal Diseases, Neurogenetics and Metabolism Unit, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
| |
Collapse
|
32
|
Šinkūnaitė L, Burbaud P, Soulages A, Vergnet S, Duval F, Solé G, Tang HMA, Le Masson G, Mathis S. Focal neurogenic muscle hypertrophy and fasciculations in multifocal motor neuropathy. Muscle Nerve 2018; 58:E36-E39. [DOI: 10.1002/mus.26185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | | | | | - Fanny Duval
- Department of Neurology; Nerve-Muscle Unit
- Centre de référence des pathologies neuromusculaires
| | - Guilhem Solé
- Department of Neurology; Nerve-Muscle Unit
- Centre de référence des pathologies neuromusculaires
| | | | - Gwendal Le Masson
- Department of Neurology; Nerve-Muscle Unit
- Centre de référence des pathologies neuromusculaires
- Department of Neurology, Movement Disorders Unit; ALS Center, CHU Bordeaux (groupe hospitalier Pellegrin), place Amélie Raba-Léon; Bordeaux France
| | - Stéphane Mathis
- Department of Neurology; Nerve-Muscle Unit
- Centre de référence des pathologies neuromusculaires
- Department of Neurology, Movement Disorders Unit; ALS Center, CHU Bordeaux (groupe hospitalier Pellegrin), place Amélie Raba-Léon; Bordeaux France
| |
Collapse
|
33
|
Lacoste I, Vergnet S, Tourdias T, Delgado LA, Le Masson G, Duval F, Mathis S. An unusual cause of spinal cord compression. J Clin Neurosci 2018. [DOI: 10.1016/j.jocn.2018.07.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
34
|
Mathis S, Magy L, Le Masson G, Richard L, Soulages A, Solé G, Duval F, Ghorab K, Vallat JM, Duchesne M. Value of nerve biopsy in the management of peripheral neuropathies. Expert Rev Neurother 2018; 18:589-602. [DOI: 10.1080/14737175.2018.1489240] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Stéphane Mathis
- Department of Neurology (Nerve-Muscle Unit), CHU Bordeaux (Pellegrin Hospital), Bordeaux, France
- National Reference Center ‘maladies neuromusculaires du grand sud-ouest’, CHU Bordeaux (Pellegrin Hospital), University of Bordeaux, Bordeaux, France
| | - Laurent Magy
- Department of Neurology, University hospital, Limoges, France
- National Reference Center for ‘rare peripheral neuropathies’, University Hospital, Limoges, France
| | - Gwendal Le Masson
- Department of Neurology (Nerve-Muscle Unit), CHU Bordeaux (Pellegrin Hospital), Bordeaux, France
- National Reference Center ‘maladies neuromusculaires du grand sud-ouest’, CHU Bordeaux (Pellegrin Hospital), University of Bordeaux, Bordeaux, France
| | - Laurence Richard
- Department of Neurology, University hospital, Limoges, France
- National Reference Center for ‘rare peripheral neuropathies’, University Hospital, Limoges, France
| | - Antoine Soulages
- Department of Neurology (Nerve-Muscle Unit), CHU Bordeaux (Pellegrin Hospital), Bordeaux, France
| | - Guilhem Solé
- Department of Neurology (Nerve-Muscle Unit), CHU Bordeaux (Pellegrin Hospital), Bordeaux, France
- National Reference Center ‘maladies neuromusculaires du grand sud-ouest’, CHU Bordeaux (Pellegrin Hospital), University of Bordeaux, Bordeaux, France
| | - Fanny Duval
- Department of Neurology (Nerve-Muscle Unit), CHU Bordeaux (Pellegrin Hospital), Bordeaux, France
- National Reference Center ‘maladies neuromusculaires du grand sud-ouest’, CHU Bordeaux (Pellegrin Hospital), University of Bordeaux, Bordeaux, France
| | - Karima Ghorab
- Department of Neurology, University hospital, Limoges, France
- National Reference Center for ‘rare peripheral neuropathies’, University Hospital, Limoges, France
| | - Jean-Michel Vallat
- Department of Neurology, University hospital, Limoges, France
- National Reference Center for ‘rare peripheral neuropathies’, University Hospital, Limoges, France
| | - Mathilde Duchesne
- National Reference Center for ‘rare peripheral neuropathies’, University Hospital, Limoges, France
- Department of Pathology, University Hospital, Limoges, France
| |
Collapse
|
35
|
Mathis S, Tazir M, Solé G, Magy L, Le Masson G, Couratier P, Ghorab K, Duval F, Lacoste I, Goizet C, Vallat JM. Some new proposals for the classification of inherited myopathies. J Neurol Sci 2018; 391:118-119. [PMID: 30103959 DOI: 10.1016/j.jns.2018.06.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2018] [Revised: 06/14/2018] [Accepted: 06/18/2018] [Indexed: 11/19/2022]
Affiliation(s)
- Stéphane Mathis
- Department of Neurology, Nerve-Muscle Unit (National reference center 'maladies neuromusculaires du grand sud-ouest'), University Hospital of Bordeaux (groupe hospitalier Pellegrin), Place Amélie Raba-Léon, 33000 Bordeaux, France
| | - Meriem Tazir
- Department of Neurology, University Hospital Mustapha Bacha, Algiers, Algeria; Laboratoire de Neurosciences, University of Algiers 1, Algiers, Algeria
| | - Guilhem Solé
- Department of Neurology, Nerve-Muscle Unit (National reference center 'maladies neuromusculaires du grand sud-ouest'), University Hospital of Bordeaux (groupe hospitalier Pellegrin), Place Amélie Raba-Léon, 33000 Bordeaux, France
| | - Laurent Magy
- Department of Neurology (National reference center 'neuropathies périphériques rares'), University Hospital Dupuytren, 2 avenue Martin Luther King, 87042 Limoges, France
| | - Gwendal Le Masson
- Department of Neurology, Nerve-Muscle Unit (National reference center 'maladies neuromusculaires du grand sud-ouest'), University Hospital of Bordeaux (groupe hospitalier Pellegrin), Place Amélie Raba-Léon, 33000 Bordeaux, France
| | - Philippe Couratier
- Department of Neurology (National reference center 'neuropathies périphériques rares'), University Hospital Dupuytren, 2 avenue Martin Luther King, 87042 Limoges, France
| | - Karima Ghorab
- Department of Neurology (National reference center 'neuropathies périphériques rares'), University Hospital Dupuytren, 2 avenue Martin Luther King, 87042 Limoges, France
| | - Fanny Duval
- Department of Neurology, Nerve-Muscle Unit (National reference center 'maladies neuromusculaires du grand sud-ouest'), University Hospital of Bordeaux (groupe hospitalier Pellegrin), Place Amélie Raba-Léon, 33000 Bordeaux, France
| | - Idoia Lacoste
- Department of Neurology, Nerve-Muscle Unit (National reference center 'maladies neuromusculaires du grand sud-ouest'), University Hospital of Bordeaux (groupe hospitalier Pellegrin), Place Amélie Raba-Léon, 33000 Bordeaux, France
| | - Cyril Goizet
- Department of Medical Genetics (National reference center 'maladies neuromusculaires du grand sud-ouest'), University Hospital of Bordeaux (groupe hospitalier Pellegrin), place Amélie Raba-Léon, 33076 Bordeaux, France; MRGM Laboratory, INSERM U1211, University of Bordeaux, place Amélie Raba-Léon, 33076 Bordeaux, France
| | - Jean-Michel Vallat
- Department of Neurology (National reference center 'neuropathies périphériques rares'), University Hospital Dupuytren, 2 avenue Martin Luther King, 87042 Limoges, France.
| |
Collapse
|
36
|
Soulages A, Duval F, Cécile B, Négrier-Leibreich ML, Solé G. Formes typiques et atypiques de MNAI : description des patients diagnostiqués au CHU de Bordeaux. Rev Neurol (Paris) 2018. [DOI: 10.1016/j.neurol.2018.01.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
37
|
Mathis S, Tazir M, Magy L, Duval F, Le Masson G, Duchesne M, Couratier P, Ghorab K, Solé G, Lacoste I, Goizet C, Vallat JM. History and current difficulties in classifying inherited myopathies and muscular dystrophies. J Neurol Sci 2018; 384:50-54. [DOI: 10.1016/j.jns.2017.10.051] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2017] [Revised: 10/30/2017] [Accepted: 10/31/2017] [Indexed: 11/27/2022]
|
38
|
Lamanna G, Aliberti R, Ambrosino F, Ammendola R, Angelucci B, Antonelli A, Anzivino G, Arcidiacono R, Barbanera M, Biagioni A, Bician L, Biino C, Bizzeti A, Blazek T, Bloch-Devaux B, Bonaiuto V, Boretto M, Bragadireanu M, Britton D, Brizioli F, Brunetti M, Bryman D, Bucci F, Capussela T, Ceccucci A, Cenci P, Cerny V, Cerri C, Checcucci B, Conovaloff A, Cooper P, Cortina Gil E, Corvino M, Costantini F, Cotta Ramusino A, Coward D, D’Agostini G, Dainton J, Dalpiaz P, Danielsson H, De Simone N, Di Filippo D, Di Lella L, Doble N, Dobrich B, Duval F, Duk V, Engelfried J, Enik T, Estrada-Tristan N, Falaleev V, Fantechi R, Fascianelli V, Federici L, Fedotov S, Filippi A, Fiorini M, Fry J, Fu J, Fucci A, Fulton L, Gamberini E, Gatignon L, Georgiev G, Ghinescu S, Gianoli A, Giorgi M, Giudici S, Gonnella F, Goudzovski E, Graham C, Guida R, Gushchin E, Hahn F, Heath H, Husek T, Hutanu O, Hutchcroft D, Iacobuzio L, Iacopini E, Imbergamo E, Jenninger B, Kampf K, Kekelidze V, Kholodenko S, Khoriauli G, Khotyantsev A, Kleimenova A, Korotkova A, Koval M, Kozhuharov V, Kucerova Z, Kudenko Y, Kunze J, Kurochka V, Kurshetsov V, Lanfranchi G, Lamanna G, Latino G, Laycock P, Lazzeroni C, Lenti M, Lehmann Miotto G, Leonardi E, Lichard P, Litov L, Lollini R, Lomidze D, Lonardo A, Lubrano P, Lupi M, Lurkin N, Madigozhin D, Mannelli I, Mannocchi G, Mapelli A, Marchetto F, Marchevski R, Martellotti S, Massarotti P, Massri K, Maurice E, Medvedeva M, Mefodev A, Menichetti E, Migliore E, Minucci E, Mirra M, Misheva M, Molokanova N, Moulson M, Movchan S, Napolitano M, Neri I, Newson F, Norton A, Noy M, Numao T, Obraztsov V, Ostankov A, Padolski S, Page R, Palladino V, Parkinson C, Pedreschi E, Pepe M, Perrin-Terrin M, Peruzzo L, Petrov P, Petrucci F, Piandani R, Piccini M, Pinzino J, Polenkevich I, Pontisso L, Potrebenikov Y, Protopopescu D, Raggi M, Romano A, Rubin P, Ruggiero G, Ryjov V, Salamon A, Santoni C, Saracino G, Sargeni F, Semenov V, Sergi A, Shaikhiev A, Shkarovskiy S, Soldi D, Sougonyaev V, Sozzi M, Spadaro T, Spinella F, Sturgess A, Swallow J, Trilov S, Valente P, Velghe B, Venditti S, Vicini P, Volpe R, Vormstein M, Wahl H, Wanke R, Wrona B, Yushchenko O, Zamkovsky M, Zinchenko A. NA62 and NA48/2 results on search for Heavy Neutral Leptons. EPJ Web Conf 2018. [DOI: 10.1051/epjconf/201817901009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
In this paper we present new results on upper limits for the search of Heavy Neutral Leptons (HNL) with data collected by NA48/2 (2003-2004), NA62-RK (2007) and NA62 (2015) CERN experiments. The data collected with different trigger configuration allow to search for both long and short living heavy neutrinos in the mass range below the kaon mass. In addition the status of the search for K+ → π+vv with the NA62 detector will be briefly presented.
Collapse
|
39
|
|
40
|
Duval F. [Diagnosis of inflammatory myopathies at the CHU Bordeaux from 2012 to 2014: implementation of novel classifications]. Med Sci (Paris) 2017; 33 Hors série n°1:46-48. [PMID: 29139386 DOI: 10.1051/medsci/201733s109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Fanny Duval
- Service de neurologie, centre de référence des maladies neuromusculaires, hôpital Pellegrin, CHU, Bordeaux, France
| |
Collapse
|
41
|
Gueudry J, Le Goff L, Compagnon P, Lefevre S, Camille A, Duval F, Francois A, Razakandrainibe R, Favennec L, Muraine M. In vivo evaluation of voriconazole eye drops efficacy in a rat Acanthamoeba polyphaga keratitis model. Acta Ophthalmol 2017. [DOI: 10.1111/j.1755-3768.2017.04435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- J. Gueudry
- Ophtalmology; Charles Nicolle University Hospital; Rouen France
| | - L. Le Goff
- Parasitology; Faculty of Medicine and Pharmacy; University of Rouen; Rouen France
| | - P. Compagnon
- Pharmacology; Charles Nicolle University Hospital; Rouen France
| | - S. Lefevre
- Ophtalmology; Charles Nicolle University Hospital; Rouen France
| | - A. Camille
- Parasitology; Faculty of Medicine and Pharmacy; University of Rouen; Rouen France
| | - F. Duval
- Parasitology; Faculty of Medicine and Pharmacy; University of Rouen; Rouen France
| | - A. Francois
- Pathology; Charles Nicolle University Hospital; Rouen France
| | - R. Razakandrainibe
- Parasitology; Faculty of Medicine and Pharmacy; University of Rouen; Rouen France
| | - L. Favennec
- Parasitology; Faculty of Medicine and Pharmacy; University of Rouen; Rouen France
| | - M. Muraine
- Ophtalmology; Charles Nicolle University Hospital; Rouen France
| |
Collapse
|
42
|
Mathis S, Duval F, Solé G, Tourdias T, Le Masson G. Chronic inflammatory demyelinating polyradiculoneuropathy-causing myelopathy. Muscle Nerve 2017; 57:E102-E103. [DOI: 10.1002/mus.25756] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2017] [Revised: 07/26/2017] [Accepted: 08/05/2017] [Indexed: 11/11/2022]
Affiliation(s)
- Stéphane Mathis
- Department of Neurology; Nerve-Muscle Unit, CHU Bordeaux (Pellegrin Hospital), Place Amélie Raba-Léon; 33000 Bordeaux France
| | - Fanny Duval
- Department of Neurology; Nerve-Muscle Unit, CHU Bordeaux (Pellegrin Hospital), Place Amélie Raba-Léon; 33000 Bordeaux France
| | - Guilhem Solé
- Department of Neurology; Nerve-Muscle Unit, CHU Bordeaux (Pellegrin Hospital), Place Amélie Raba-Léon; 33000 Bordeaux France
| | - Thomas Tourdias
- Department of Neuroradiology; CHU Bordeaux (Pellegrin Hospital); Bordeaux France
- INSERM U1215; University of Bordeaux; Bordeaux France
| | - Gwendal Le Masson
- Department of Neurology; Nerve-Muscle Unit, CHU Bordeaux (Pellegrin Hospital), Place Amélie Raba-Léon; 33000 Bordeaux France
| |
Collapse
|
43
|
Costagliola A, Venault L, Deroche A, Vermeulen J, Duval F, Blain G, Vandenborre J, Fattahi-Vanani M, Vigier N. Influence of Nitric Acid on the Helium Ion Radiolysis of Aqueous Butanal Oxime Solutions. J Phys Chem A 2017; 121:5069-5078. [DOI: 10.1021/acs.jpca.6b12630] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- A. Costagliola
- SUBATECH, UMR
6457, Ecole des Mines de Nantes, CNRS/IN2P3, Université de Nantes, 4, Rue Alfred Kastler, La chantrerie BP 20722, 44307 Nantes cedex 3, France
- CEA,
Nuclear Energy Division, RadioChemistry and Process Department, Marcoule Center, 30207 Bagnols Sur Cèze, France
| | - L. Venault
- CEA,
Nuclear Energy Division, RadioChemistry and Process Department, Marcoule Center, 30207 Bagnols Sur Cèze, France
| | - A. Deroche
- CEA,
Nuclear Energy Division, RadioChemistry and Process Department, Marcoule Center, 30207 Bagnols Sur Cèze, France
| | - J. Vermeulen
- CEA,
Nuclear Energy Division, RadioChemistry and Process Department, Marcoule Center, 30207 Bagnols Sur Cèze, France
| | - F. Duval
- CEMHTI Site Cyclotron, CNRS, 3A rue de la Férollerie, 45071 Orléans Cédex 2, France
| | - G. Blain
- SUBATECH, UMR
6457, Ecole des Mines de Nantes, CNRS/IN2P3, Université de Nantes, 4, Rue Alfred Kastler, La chantrerie BP 20722, 44307 Nantes cedex 3, France
| | - J. Vandenborre
- SUBATECH, UMR
6457, Ecole des Mines de Nantes, CNRS/IN2P3, Université de Nantes, 4, Rue Alfred Kastler, La chantrerie BP 20722, 44307 Nantes cedex 3, France
| | - M. Fattahi-Vanani
- SUBATECH, UMR
6457, Ecole des Mines de Nantes, CNRS/IN2P3, Université de Nantes, 4, Rue Alfred Kastler, La chantrerie BP 20722, 44307 Nantes cedex 3, France
| | - N. Vigier
- AREVA NC, BG aval/BO recyclage/RDP, Tour AREVA, 1 place Jean Milier, 92084 Paris La Défense Cedex, France
| |
Collapse
|
44
|
Sole G, Duval F, Lacoste-Dagens M, Metay C, Rouanet-Larriviere M, Damon-Perriere N, Négrier-Leibreich ML. Cas clinique 5. Rev Neurol (Paris) 2017. [DOI: 10.1016/j.neurol.2017.01.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
45
|
Blanc CL, Lemaire J, Duval F, Théoleyre MA, Pareau D. Purification of pentoses from hemicellulosic hydrolysates without neutralization for sulfuric acid recovery. Sep Purif Technol 2017. [DOI: 10.1016/j.seppur.2016.10.042] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
46
|
Taisne N, Desnuelle C, Juntas Morales R, Ferrer Monasterio X, Sacconi S, Duval F, Sole G, Flipo RM, Lacour A, Vermersch P, Cardon T. Bent spine syndrome as the initial symptom of late-onset Pompe disease. Muscle Nerve 2016; 56:167-170. [DOI: 10.1002/mus.25478] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/14/2016] [Indexed: 11/07/2022]
Affiliation(s)
- Nicolas Taisne
- Rhumatologie, Hôpital Roger Salengro, Université de Lille 2, Centre Hospitalier Régional Universitaire de Lille; Lille France
| | - Claude Desnuelle
- Syst'me nerveux périphérique, muscle et SLA, Hopital Pasteur 2, CHU de Nice; Nice France
| | - Raul Juntas Morales
- Hôpital Gui-de-Chauliac, service de neurologie, clinique du motoneurone, Inserm 1051; 34925 Montpellier France
| | | | - Sabrina Sacconi
- Syst'me nerveux périphérique, muscle et SLA, Hopital Pasteur 2, CHU de Nice; Nice France
| | - Fanny Duval
- Neurologie, Hôpital Pellegrin, CHU Bordeaux; Bordeaux France
| | - Guilhem Sole
- Neurologie, Hôpital Pellegrin, CHU Bordeaux; Bordeaux France
| | - René Marc Flipo
- Rhumatologie, Hôpital Roger Salengro, Université de Lille 2, Centre Hospitalier Régional Universitaire de Lille; Lille France
| | - Arnaud Lacour
- Universitaire Lille, CHU Lille, Clinique Neurologique, Centre de référence maladies rares d'origine neuro-musculaire; Lille France
| | - Patrick Vermersch
- Universitaire Lille, CHU Lille, Clinique Neurologique, Centre de référence maladies rares d'origine neuro-musculaire; Lille France
| | - Thierry Cardon
- Rhumatologie, Hôpital Roger Salengro, Université de Lille 2, Centre Hospitalier Régional Universitaire de Lille; Lille France
| |
Collapse
|
47
|
Lemaire J, Blanc CL, Duval F, Théoleyre MA, Pareau D. Purification of pentoses from hemicellulosic hydrolysates with sulfuric acid recovery by using electrodialysis. Sep Purif Technol 2016. [DOI: 10.1016/j.seppur.2016.04.030] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
48
|
Costagliola A, Venault L, Deroche A, Garaix G, Vermeulen J, Omnee R, Duval F, Blain G, Vandenborre J, Fattahi-Vanani M, Vigier N. Radiation chemical behavior of aqueous butanal oxime solutions irradiated with helium ion beams. Radiat Phys Chem Oxf Engl 1993 2016. [DOI: 10.1016/j.radphyschem.2015.10.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Auzou N, Dujardin K, Biundo R, Foubert-Samier A, Barth C, Duval F, Tison F, Defebvre L, Antonini A, Meissner WG. Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson's disease dementia. Parkinsonism Relat Disord 2015; 21:1273-7. [PMID: 26305998 DOI: 10.1016/j.parkreldis.2015.08.013] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Revised: 07/20/2015] [Accepted: 08/13/2015] [Indexed: 11/24/2022]
Abstract
INTRODUCTION Dementia is an exclusion criterion in current consensus diagnostic criteria, while growing evidence suggests the occurrence of cognitive dysfunction and even dementia in multiple system atrophy (MSA) patients. The main goal of this study was to determine if Movement Disorder Society (MDS) Parkinson's disease dementia (PDD) LEVEL-1 criteria are useful in screening for dementia in MSA patients compared to full cognitive testing (LEVEL-2 criteria). METHODS In this retrospective study, MDS diagnostic criteria for PDD were applied in 111 MSA patients from three centres. LEVEL-1 evaluation (short screening test) was compared to LEVEL-2 examination (extensive neuropsychological gold standard assessment). Sensitivity, specificity, positive and negative predictive values were calculated for LEVEL-1 compared to LEVEL-2. Two Mini Mental State Examination (MMSE) cut-off scores were evaluated (<26 according to MDS procedures for the diagnosis of PDD and <27 which has proven more sensitive in a recent study proposing a short procedure for PDD screening). RESULTS According to these criteria, 11.7% of MSA patients were demented on LEVEL-2 examination. LEVEL-1 examination showed strong specificity (96.9%) and negative predictive value (94.1%), while sensitivity (53.8%) and positive predictive (70%) value were moderate compared to LEVEL-2 evaluation. Sensitivity increased to 84.6% when using a MMSE threshold <27 for LEVEL-1. Executive dysfunction was the main prevalent finding (52% of all patients), while impairment of memory (15%), language (14%) and visuospatial functions was less frequent (13%). CONCLUSION Our findings suggest that the MDS PDD short screening test may be useful for the diagnosis of MSA dementia.
Collapse
Affiliation(s)
- Nicolas Auzou
- Service de Neurologie, CHU de Bordeaux, Bordeaux, France; Univ. de Bordeaux, Laboratoire de Psychologie, Santé et Qualité de Vie, EA4139, Bordeaux, France
| | - Kathy Dujardin
- Service de Neurologie et Pathologies du Mouvement, CHRU de Lille, France; Inserm U1171, Troubles cognitifs dégénératifs et vasculaires, Université de Lille, Lille, France
| | - Roberta Biundo
- Parkinson and Movement Disorders Unit, Fondazione Ospedale San Camillo, Venice, Italy
| | - Alexandra Foubert-Samier
- Service de Neurologie, CHU de Bordeaux, Bordeaux, France; Centre de référence atrophie multisystématisée, CHU de Bordeaux, Bordeaux, France; Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
| | - Caroline Barth
- Centre de référence atrophie multisystématisée, CHU de Bordeaux, Bordeaux, France
| | - Fanny Duval
- Service de Neurologie, CHU de Bordeaux, Bordeaux, France
| | - François Tison
- Service de Neurologie, CHU de Bordeaux, Bordeaux, France; Centre de référence atrophie multisystématisée, CHU de Bordeaux, Bordeaux, France; Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
| | - Luc Defebvre
- Service de Neurologie et Pathologies du Mouvement, CHRU de Lille, France; Inserm U1171, Troubles cognitifs dégénératifs et vasculaires, Université de Lille, Lille, France
| | - Angelo Antonini
- Parkinson and Movement Disorders Unit, Fondazione Ospedale San Camillo, Venice, Italy
| | - Wassilios G Meissner
- Service de Neurologie, CHU de Bordeaux, Bordeaux, France; Centre de référence atrophie multisystématisée, CHU de Bordeaux, Bordeaux, France; Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
| |
Collapse
|
50
|
Proudnikova X, Hode Y, Gonzalez F, Duval F. L’anhédonie dans la dépression unipolaire et bipolaire. Eur Psychiatry 2014. [DOI: 10.1016/j.eurpsy.2014.09.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Abstract
Les symptômes anhédoniques décrits dans la schizophrénie et dans la dépression pourraient être de nature différente [1]. Cette hypothèse a été explorée avec l’échelle EETP, différenciant l’anhédonie consommatoire (liée à l’éprouvé du plaisir) et l’anhédonie d’anticipation (liée à la motivation à rechercher le plaisir). Les patients souffrant de schizophrénie auraient un score plus bas à la composante anticipatoire [2]. Cette étude vise à évaluer les caractéristiques de l’anhédonie chez des patients dépressifs non psychotiques.MéthodeVingt-huit patients hospitalisés pour un épisode dépressif unipolaire ou bipolaire ont été inclus, (23 femmes, 5 hommes) âgés de 32 à 61 ans. Ils ont été évalués à l’aide de la MADRS et de l’EETP. Les corrélations entre les scores à la MADRS et ceux du plaisir anticipatoire et du plaisir consommatoire ont été analysées avec le test non paramétrique de Spearman.RésultatsLe score MADRS est inversement corrélé avec le score du plaisir consommatoire chez les patients avec un trouble dépressif unipolaire alors qu’il inversement corrélé avec le score du plaisir anticipatoire chez les patients bipolaires.ConclusionDans les dépressions bipolaires, l’anhédonie a une forme différente de celle rencontrée dans la dépression unipolaire. Cela pourrait signifier que la dépression bipolaire est plus en rapport avec un déficit motivationnel comme dans la schizophrénie. Cette étude montre aussi l’intérêt d’une utilisation plus systématique de l’échelle EETP dans les troubles thymiques. Cela pourrait aider à orienter l’action thérapeutique sur les mécanismes de l’éprouvé du plaisir ou sur ceux de la motivation.
Collapse
|